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Abstract 
McCall, Joshua D (Ph.D. Chemical Engineering) 
Department of Chemical and Biological Engineering, University of Colorado at Boulder. 
 
Poly(ethylene glycol) based biomaterial platforms for guiding cell behavior through control of 
presentation and release of bioactive, therapeutic proteins 
 
Thesis directed by Dr. Kristi S. Anseth 
 
 Poly(ethylene glycol) (PEG) based biomaterials offer a number of advantages for 
applications in biomedical technology, including drug delivery and tissue engineering.  PEG is 
notable for both its hydrophilicity and bioinert properties, and is widely used to create hydrogels 
used for 3D cell culture.  There is growing interest in strategies to introduce biological 
functionality into PEG-based materials, in order to develop platforms to study the complex 
biochemical and biomechanical cues that govern cell behavior in physiologically relevant 
context.  This thesis explores photopolymerization conditions for hydrogel synthesis that 
maintain a high degree of bioactivity for proteins in-situ.  Such reactions are then utilized to 
create hydrogels capable of directing cell fate and behavior.   
 Photopolymerization conditions for the formation of hydrogels were characterized, as 
these reactions are widely used for protein encapsulation.  First, the role of affinity peptides was 
studied during photoencapsulation of the cytokine transforming growth factor β (TGFβ). When 
peptides with affinity for TGFβ were included in monomer solutions, they increased the amount 
of soluble, bioactive protein released from PEG diacrylate hydrogels formed via a chain-growth 
polymerization.  We then studied protein protection during photopolymerization of step-growth 
networks using a thiol-norbornene reaction.  Thiol-ene reactions were shown to be milder than 
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acrylate chain-growth, as they fully maintained the bioactivity of TGFβ and lysozyme.  Protein 
deactivation was correlated to total photoinitiated radical concentrations in order to more fully 
characterize reaction conditions that maximized protein protection. 
 We then applied this knowledge to create biomaterials that incorporated covalently 
linked, bioactive proteins capable of directing complex cellular functions.  TGFβ was thiolated 
via reaction with 2-iminothiolane, a modification that had no impact on bioactivity.  This thiol-
functionalized protein could then be readily linked into hydrogels using either thiol-acrylate or 
thiol-ene polymerizations.  When human mesenchymal stem cells were encapsulated into 
tethered TGFβ hydrogels, the growth factor induced chondrogenic differentiation at levels 
similar to or exceeding that of soluble delivery.  Further, tethered TGFβ hydrogels were used to 
culture valvular interstitial cells in order to study the combined roles of substrate elasticity and 
immobilized TGFβ play in activation of myofibroblast phenotype.  The photopolymerization 
conditions and resulting functionalized hydrogels developed in this thesis demonstrate the use of 
PEG hydrogels to investigate complex cell-material interactions of interest in tissue engineering 
applications. 
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Chapter 1.  
 
Introduction 
 
 
1.1 Overview 
 
Hydrogels hold great promise for utilization in the field of regenerative medicine, 
especially as cell and drug delivery vehicles.  These versatile, highly swollen polymer networks 
are characteristically formed with a high water content, via a variety of cytocompatible, aqueous 
chemistries1-6.  By tuning polymeric properties like elasticity and diffusivity, hydrogels provide a 
facile method for creating three-dimensional cell-laden scaffolds with properties similar to many 
soft tissues.  Unlike traditional cellular biology approaches, where cells are cultured on rigid, 
two-dimensional surfaces (e.g., petri dishes, tissue culture flasks, etc), hydrogels provide a 
powerful tool to study cellular behavior in three-dimensional systems that more closely resemble 
the native extracellular matrix (ECM).   
Poly(ethylene glycol) (PEG)-based hydrogels are one of the most widely studied 
biomaterial platforms, as PEG offers a number of desirable properties as a scaffold choice, 
including tunable mechanics2, 7, 8, low protein adsorption9-11, and high viability of encapsulated 
cells4, 12-14.  Further, PEG hydrogels can be tailored to provide a sustained and local presentation 
of proteins to cells15-20.  Many such biological macromolecules, including hormones, growth 
factors, and others, function in vivo to guide a host of cellular functions, making them a 
promising tool for tissue engineering.  However, protein signaling is a complicated process and 
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often necessitates delivery platforms capable of both spatial and temporal control of their 
presentation.  This thesis is broadly focused on photopolymerization schemes of PEG hydrogels 
that maintain a high degree of bioactivity for proteins encapsulated in situ, with the ultimate goal 
of developing materials capable of presenting bioactive protein signals to study and direct cell 
behavior.  
 
1.2 Poly(ethylene glycol) based biomaterials 
 Poly(ethylene glycol) (PEG) is an attractive choice for biomaterials, as PEGs have been 
utilized in a variety of FDA-approved applications including food additives, emulsifiers, anti-
thrombotic coatings, and in PEGylation of therapeutic proteins.   The carbon-carbon-oxygen mer 
(Figure 1.1) is imminently hydrophilic; in aqueous environments, the ethylene glycol repeat unit 
binds water molecules, thereby limiting sites available for adsorption of other species10, 21.   
 Edward Merrill is often credited for pioneering the use of PEG in biomedical 
applications.  While studying the viscosity of blood in the early 1960s, he observed rapid clot 
formation upon contact with most membrane materials in use at the time.  In contrast, he found 
PEG was impressively bioinert and had clear application as an anti-thrombotic material, a 
discovery that facilitated the development of early biomedical technologies like kidney dialysis 
and blood oxygenators22, 23.  Some sixty years later, PEG-based polymers are ubiquitously used  
in biomedical applications. 
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 A   B.  
Figure 1.1.  A) linear PEG structure, and B) multi-arm PEG structure 
  
 PEG chains can be functionalized with reactive groups and subsequently used to create a 
crosslinked material, as shown in Figure 1.1 B.  Many reactive groups have been used to form 
crosslinked PEG hydrogels, including amines, carboxylic acids, thiols, (meth)acrylates, 
maleimides, vinyl sulphones, and others.  This vast array of functionalized PEGs provides a 
similarly diverse range of mechanical properties in resulting hydrogels.  Hydrogel crosslinking 
density can be tuned by choice of PEG molecular weight, e.g. diacrylated PEG of molecular 
weight 2,000 Da forms a hydrogel with a higher crosslinking density than does 10,000 Da PEG 
diacrylate.  Crosslinking density can also be tuned through differences in monomer functionality 
and number of PEG arms.  As an example, a PEG hydrogel formed with 4-arm PEG 
(Mn=10,000) norbornene can be crosslinked with a linear bis(thiol) (Mn=2,000) via a thiol-ene 
polymerization; crosslinking density can be tuned by changing the molecular weight of the 
bis(thiol) crosslink, the molecular weight of the 4-arm PEG ene, or by increasing the number of 
arms on either species, as shown in Figure 1.1.  The utility of PEG hydrogels is enhanced 
through such facile control of crosslinking density, as this in turn controls important mechanical 
properties, including elasticity, diffusivity, and degradation7, 24-30. 
	   4	  
 
1.3 Photopolymerization approaches for forming PEG hydrogels 
 While hydrogels can be synthesized from a variety of chemistries, photopolymerization 
offers a number of distinct advantages.  Photoinitiated reactions can proceed under mild 
conditions, notably in aqueous systems at physiological temperature and pH.  These approaches 
are widely used for polymerization in the presence of sensitive encapsulants, such as cells or 
proteins due to the high cytocompatibility afforded by photoinitiation1, 4, 6.  Of further interest, 
photoinitiated polymerizations provide precise spatial and temporal control, extending the 
versatility of materials formed from such reaction schemes.  For radically mediated 
photopolymerizations, radicals are generated from an initiator species according to Equation 1.1: 
      
€ 
Ri =
2 fφελI
NAhν
[Ci]        (1.1) 
where Ri is the rate of primary radical generation, as a function of Ci, the concentration of 
unreacted initiator.  The initiator efficiency, f, and quantum yield, Φ, are characteristic for each 
initiator.  Molar absorbtivity, ε, describes the amount of light absorbed by an initiator at a given 
wavelength, λ, while the intensity of incident light, I, is a measure of the amount of radiation 
delivered to the system for initiation.  For biocompatibility, light wavelengths and intensities are 
critical parameters: wavelengths above 365 nm are generally considered cytocompatible, and 
initiators with high absorbtivity at these longer wavelengths allow for reduction in the dose of 
radiation, thereby increasing cell viability1, 4, 31. 
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1.3.1 (Meth)Acrylate chain-growth polymerization 
 
Figure 1.2 – Schematic of an acrylate chain-growth reaction and resulting network structure 
 One of the most common photochemical approaches to forming PEG hydrogels is the 
radically-mediated chain-growth reaction of (meth)acrylated PEG species.  Photoinitiation of 
acryl chain-growth is widely used, via a number of water-soluble light-cleavable initiator 
species1, 4.  In the presence of a radical source, both acrylate and methacrylate functional groups 
can undergo chain-growth polymerization.  Following radical transfer to the vinyl carbon of the 
carbon-carbon double bond, the radical propagates until termination produces a dead polymer 
chain32.  For tetrafunctional monomers, e.g. PEG di(meth)acrylate, the reaction results in a 
crosslinked polymer material.    Although susceptible to oxygen inhibition33, the (meth)acrylate 
chain-growth reaction is considered a robust method for synthesizing hydrogels at dilute 
functional group concentration in aqueous environments, while maintaining viability of in-situ 
encapsulated cells and proteins34.  When mesenchymal stem cells were encapsulated in PEG 
hydrogels formed through photopolymerization of acrylated-PEG monomer, Nuttelman et al. 
reported >95% viability of encapsulated cells13.   
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1.3.2. Thiol-ene step-growth polymerization 
 
Figure 1.3 – Schematic of a thiol-ene step-growth reaction and resulting network structure 
 In contrast to (meth)acrylate homo-polymerization, thiol-ene “click” reactions proceed 
via a step-growth mechanism and require two unique monomers.  The reaction occurs through 
two steps: upon cleavage of an initiator species, radicals transfer to a thiol in solution, creating a 
thiyl radical.  Propagation occurs with the addition of the thiyl radical across a carbon-carbon 
double bond, the ene.  If the ene is selected properly, the carbon radical cannot homopolymerize, 
but instead, can only chain transfer back to another thiol, regenerating a reactive thiyl radical.  
This unique reaction allows step growth of PEG networks via a radical-mediated process2.  As an 
example, PEG hydrogels have been photopolymerized using this reaction scheme with four-arm 
PEG-norbornene and bis(thiol) crosslinkers, with high maintenance of cell viability and 
function14.  The resulting ideal polymer networks possess macroscale homogenous mechanical 
properties, making them an attractive choice for encapsulation platforms for biologics.  Further, 
the thiol-ene reaction is not oxygen inhibited and can be used to rapidly form hydrogels using 
low initiator concentrations and/or light doses2, 35, and this approach has been utilized to 
synthesize hydrogels for encapsulation of radically sensitive payloads, including cells14, 36-38 and 
bioactive proteins39. 
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1.3.3 Thiol-acrylate mixed-mode polymerization 
  
Figure 1.4 – The thiol-acrylate polymerization scheme and resulting polymer network 
 As the name suggests, the thiol-acrylate photopolymerization is a hybrid scheme 
combining aspects of chain- and step-growth.  While the reaction can propagate via a chain-
growth mechanism, thiol present in the monomer solution can abstract a radical to produce a 
thiyl species.  This thiyl can then chain-transfer to an unreacted acrylate, creating an acryl radical 
that can further propagate.  The chain-transfer constant for this mixed mode has been reported on 
the order of 1.5 - 240-42 and has been utilized to incorporate numerous thiol-functionalized 
molecules into PEG hydrogels. 
 Both the thiol-ene and mixed-mode thiol-acrylate photopolymerization approaches 
involve covalent reactions of thiol-containing species.  One mutual benefit these synthetic routes 
is the facile incorporation of thiol-containing biomolecules into hydrogel materials. 
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1.4 Introduction of biologically active moieties into synthetic polymer materials 
 There is growing interest in ways to incorporate biological cues into synthetic cell 
scaffold biomaterials, in order to study more complex cell-material interactions in a 
physiologically relevant three-dimensional model.  In-vivo, a host of signals from the cellular 
microenvironment influence cell behavior, including cell-cell, cell-matrix, and cell-signaling 
protein interactions43.  Hydrogels synthesized from bioinert materials like PEG represent a blank 
slate for cell culture, one that can be functionalized via chemical modification to introduce 
biological cues.  In this way, it is possible to isolate and characterize individual cues, like 
adhesion ligands or substrate elasticity, and the role that they play in guiding cell function.  PEG 
hydrogels formed via acrylate chain-growth or thiol-ene step-growth polymerization are 
particularly attractive for such studies, as thiol-functionalized biomolecules can be covalently 
incorporated into the polymer itself. 
 
1.4.1 Peptide-functionalized hydrogels 
 Peptides are short polymers comprised of amino acids linked by amide bonds.  Peptides 
can be synthesized at yield and quantity similar to that of small molecules, and in many cases can 
provide functions similar to that of a full-length protein.  This property makes peptide 
functionalization an attractive choice for introducing biological cues into synthetic hydrogels.   
 Perhaps the most extensively studied example of peptide functionalization is that of the 
integrin-binding peptide sequence Arg-Gly-Asp-Ser (RGDS), isolated from the ECM protein 
fibronectin.  This peptide has been identified as an adhesion site used by many adherent cells, 
and binds with a number of integrins44 expressed by a multitude of cell types.  The inclusion of 
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RGDS peptides in PEG hydrogels provides an adhesion site and mimics the native cellular 
microenvironment, where ECM proteins facilitate integrin binding.   
 The native ECM is a dynamic structure, and cells are capable of remodeling their 
pericellular microenvironment through enzymatic degradation.  Matrix-metalloproteinases 
(MMPs) are cell-secreted enzymes capable of degrading specific peptide sequences of ECM 
proteins like collagen, fibronectin, laminin and others.  Numerous peptide sequences susceptible 
to MMP-cleavage have been identified, including MMP-1 cleavable peptides Val-Arg-Asn 
(VRN) and Ala-Pro-Gly-Leu (APGL), among others.  Including these MMP-degradable peptide 
sequences as crosslinkers in synthetic PEG presents a facile method to allow cell-mediated 
degradation of a synthetic matrix45.  
 Alternatively, peptides have been exploited for use as protein affinity ligands.  Peptide 
sequences with binding affinity for proteins of interest can be isolated via a variety of techniques, 
including but not limited to bacteria phage-display screening or isolation of short sequences from 
longer proteins known to bind a target.  Such affinity peptides bind reversibly with a target 
protein, and the interactions are governed through kinetic rates depicted in Equation 1.2: 
€ 
Protein +  Ligand ⇔
krev
k forw
 Protein - Ligand
KD =
krev
k forw  (1.2)
 
Incorporation of such affinity ligands has been used to functionalize PEG hydrogels used for 
protein delivery and inhibition.  The peptide sequence Lys-Arg-Thr-Gly-Gln-Tyr-Lys-Leu 
(KRTGQYKL) has binding affinity for the growth factor bFGF.  When this peptide was 
covalently incorporated in PEG hydrogels, the resulting polymer matrix was effective in 
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controlling the release of photoencapsulated growth factor over time scales ranging from 1 to 4 
weeks19.   
 Peptide mimics of full proteins provide another application for peptide-functionalized 
hydrogels.  Numerous peptide sequences have been reported as passable analogs of full-length 
proteins and can be produced at a fraction of recombinant expression approaches required for 
proteins.  Peptide mimics have been reported for the cytokines BMP-2 and BMP-7,46, 47 both of 
which are implicated in the osteogenic differentiation of human mesenchymal stem cells.  Such 
discoveries and reports regarding new peptide sequences open opportunities for the creation of 
innovative peptide functionalized matrices to direct critical cellular functions. 
  
1.4.2 Protein-functionalized hydrogels 
 While peptide-functionalized hydrogels have been effective tools for introducing 
biochemical cues into synthetic hydrogels, methods to covalently link full, bioactive proteins into 
hydrogel matrices are of interest, as they can potentially provide a more physiologically relevant 
signal to encapsulated cells.  Such an approach provides a versatile method to precisely control 
protein concentrations, while limiting protein diffusion out of the target site, potentially 
minimizing undesirable collateral interactions with surrounding tissues. 
 A number of proteins have been successfully tethered into hydrogel materials for tissue 
engineering applications15, 16.  Valvular endothelial growth factor (VEGF) has been acrylated and 
covalently immobilized in PEG diacrylate hydrogels, in order to promote endothelial cell 
tubulogenesis48, and platelet-derived growth factor  (PDGF) has been similarly incorporated into 
PEGDA hydrogels with results demonstrating promotion of angiogenesis and tubulogenesis49. 
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 TGFβ is an attractive target for tissue engineering application, as it is known to regulate a 
diverse number of cellular responses in a wide range of biological systems.  Mann et al. 
acrylated TGFβ using acryl-PEG-NHS chemistry and subsequently crosslinked this growth 
factor into PEGDA hydrogels50.  When smooth muscle cells were encapsulated in PEG 
hydrogels with tethered TGFβ, the cells produced ECM components indicative of TGFβ 
stimulation, at levels higher than that of a control system, namely TGFβ that was dosed solubly.  
More recently, affinity peptides binding to TGFβ receptors were immobilized on glass 
substrates, in an effort to spatially concentrate receptors to, in effect, spatially pattern TGFβ51.  
This approach sensitized mouse mammary gland cells, as surfaces patterned with the peptides 
promoted αSMA upregulation at levels similar to that of solubly delivered TGFβ.  Finally, TGFβ 
and interleukin 1β were thiolated by Hume et al.52 and covalently tethered into PEG diacrylate 
hydrogels to form material surfaces capable of down regulating dendritic cell response.   
 
1.5 The cytokine transforming growth factor beta (TGFβ) 
 The elucidation of in-vivo protein signaling between organs and systems is a relatively 
recent achievement of modern biology.  The name Pavlov will always be associated with 
conditional responses of the nervous system (as well as slobbering dogs); he was himself a 
stringent opponent to the idea of non-nervous system signaling, as were most biologists of the 
time.  In their seminal experiment in 1902, Ernest Starling and William Bayliss removed the 
nerves from the intestine of a canine, then simulated digestion and observed the production of 
pancreatic juice.  Despite the lack of a nervous system connection between the two organs, there 
was no decrease in pancreatic function.  This was the first demonstration of the role played by 
proteins in controlling cell and organ function53.  The ramifications of this discovery reverberate 
	   12	  
more than a century later, as medical technology continues to pursue and exploit such complex 
signaling for the treatment of disease. 
 Many classes of signaling proteins have since been characterized, including hormones, 
antibodies, and growth factors.  The term ‘growth factor’ is vestigial, as these proteins and 
factors were originally known for their ability to illicit changes, such as an increase in the rate of 
cellular proliferation54, 55.  More appropriately, this class of cell-secreted proteins is now more 
commonly referred to as ‘cytokines,’ from the Greek words for ‘cell’ and ‘movement.’  
Cytokines can regulate a variety of complex cell behaviors and play an important role in both 
homeostasis and pathologies.  While they are potent, with functional concentrations in the nano- 
to picomolar range, they are unstable in circulation, often with serum half-lives on the order of 
minutes18, 56.  Another limitation is that receptors for many cytokines are widely conserved 
among multiple cell types17, 18, 57, 58, restricting the utility of systemic dosage.  However, as these 
proteins are designed to incite cellular responses, they are increasingly targeted for applications 
in regenerative medicine and tissue engineering16, 17, 19, 56, 57, 59-62.   
 
Figure 1.6 TGFβ signaling pathway (adapted from Sigma Aldrich) 
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 Transforming growth factor beta (TGFβ) was first isolated in 1983 and has since been 
widely studied, as this 25 kDa protein and other members of the TGF super-family play an 
important role in a vast array of cellular processes55, 58.  TGFβ is found in three different 
isoforms, typically referred to TGFβ-1, TGFβ-2, and TGFβ-3.  While TGFβ-2 only functions in 
conjunction with TGFβ1/3, isoforms 1 and 3 are almost identical in bioactivity and sequence63, 
and TGFβ-1 is used exclusively in this work.  TGFβ is clearly implicated in regulation of 
proliferation, differentiation, motility, adhesion, and apoptosis55, 58, 63.  Receptors for TGFβ are 
highly conserved across systems and species, as quoted from Massague’s 1998 review: 
“Expressed in complex temporal and tissue-specific patterns, TGFβ and related factors play a 
prominent role in the development, homeostasis, and repair of virtually all tissues in organisms, 
from fruitfly to human.58”  TGFβ is also implicated in both pathology and wound response, 
including fibrosis, activation of immune response, blood vessel development, ECM secretion and 
remodeling, and myocardial homestasis63, 64. 
 Of specific interest in this thesis, TGFβ can induce differentiation of hMSCs, promoting 
a chondrocyte-like phenotype.  Chondrocytes are the primary cell type found in articular 
cartilage tissue.  This tissue, composed of polysaccharides known as glycosaminoglycans 
(GAGs) and collagen type II, is avascular, a factor that leads to the limited healing capacity 
observed for damaged cartilage.  hMSCs cultured in media augmented with soluble TGFβ 
undergo chondrogenic differentiation, resulting in neochondrocytes capable of secreting GAGs 
and collagen-II.  As hMSCs can be readily isolated from patient bone marrow, this approach has 
potential as a tissue-engineering solution for cartilage repair.   
 TGFβ is also known to promote activation of valvular interstitial cells (VICs), where the 
cells undergo a transition from a quiescent, fibroblast-like state into a myofibroblast phenotype65-
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68.  This myofibroblast population helps repair damaged heart valve tissues following injury, 
secreting ECM components to replace and reorganize the matrix.  However, sustained activation 
of these cells can itself lead to valve failure, as the leaflets stiffen and can cease to properly 
regulate blood flow through the aorta66, 69, 70.  VIC activation can be initiated by both substrate 
elasticity and TGFβ dosage50, 71-75, and indeed, TGFβ is immobilized in calcific nodules that 
form in response to prolonged activation72.  Less understood is the crosstalk between these two 
factors, as elucidation of the roles played by substrate stiffness and TGFβ concentration requires 
a model with independent control of each. 
   
1.6 Approach of this thesis 
 In this thesis, we broadly investigate photopolymerization methods and conditions for 
synthesis of PEG hydrogels that maintain the bioactivity of in-situ proteins.  We use these 
reaction parameters to demonstrate the utility of PEG hydrogels for both encapsulation and 
covalent tethering of TGFβ and it application in directing cell function.  The specific objectives 
and experimental plan of this thesis are discussed in greater detail in Chapter 2. 
 In Chapter 3, we focus on the use of affinity peptides and their ability to increase the 
recovery and release of active TGFβ that is photoencapsulated in PEG hydrogels formed via a 
chain-polymerization.  Two peptides with affinity for TGFβ are identified and characterized.  
When included in monomer formulations, we study how affinity peptide sequences increase the 
amount of soluble, bioactive TGFβ released from the hydrogel following photoencapsulation.  
 In Chapter 4, we further characterize photoencapsulation reaction conditions that 
preserve the bioactivity of in-situ proteins.  PEG hydrogels are formed using either a chain-
growth (acrylate) or step-growth (thiol-ene) mechanism.  Loss of protein bioactivity from 
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photogenerated primary radicals is characterized and compared to destruction in the presence of 
a competing acryl chain-growth or thiol-ene step-growth polymerization. 
 After studying photopolymerization conditions that maximize in-situ protein bioactivity, 
we then apply this knowledge by covalently crosslinking bioactive proteins into PEG hydrogels.  
In Chapter 5, we show the utility of this approach by developing a biomaterial platform capable 
of promoting chondrogenic differentiation of encapsulated hMSCs.  Thiolated TGFβ is 
incorporated into PEGDA hydrogels using a thiol-acrylate polymerization.  A reporter cell line is 
first utilized to demonstrate the bioactivity of tethered TGFβ in 3D culture.  Then, hMSCs are 
encapsulated in these tethered TGFβ hydrogels to study how tethered growth factors promote 
their chondrogenic differentiation, as evaluated via immunohistological analysis of secreted 
proteins and stem-cell markers.  Chondrogenesis of hMSCs encapsulated in tethered TGFβ gels 
is compared to that of cells encapsulated in blank PEG gels and dosed with higher amounts of 
soluble TGFβ.  In Chapter 6, we use a similar approach in PEG hydrogels created using a thiol-
ene polymerization.  PEG hydrogels are formed with excess [ene] relative to [SH], allowing a 
subsequent reaction to couple thiolated TGFβ.  Bioactive proteins are then spatially patterning 
through the use of photolithographic techniques.  We demonstrate the utility of this approach by 
studying the fibroblast to myofibroblast activation of valvular interstitial cells. 
 Chapter 7 then concludes with a brief summary of the full scope of the work included 
herein, as well as preliminary results indicating the feasibility of future applications for this 
knowledge.  Collectively, the results presented in this thesis combine to demonstrate facile 
methods for photoencapsulation of bioactive proteins capable of directing multiple cell functions. 
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Chapter 2 
 
Thesis Objectives 
 
 
	  
 Broadly, this thesis aims to develop hydrogel platforms capable of presenting bioactive 
proteins to cells in a physiologically relevant context.  To this end, we investigate 
photopolymerizations as a facile method to either encapsulate or covalently tether signaling 
proteins in PEG hydrogel scaffolds, with the goal of minimizing the loss of protein bioactivity 
during such reactions.  Synthetic polymeric materials are ubiquitously utilized for both cell 
encapsulation and drug delivery, as they can be easily fabricated with a wide array of 
biomechanical properties via mild synthesis conditions.  Further, synthetic materials like PEG 
function as a “blank slate”, one that provides minimal biological cues to encapsulated or 
proximal cells, and a unique system from which to introduce protein signals and ask basic 
questions about their influence on specific cellular functions. 
 In-vivo, the cellular microenvironment presents a complex milieu of external cues that 
can guide behavior and influence cell fate.  These signals can be from the ECM itself, e.g. 
integrin-adhesion site binding or tissue elasticity; cell-cell contact can also play a role in cell 
function, through cell-adhesions and other mechanisms.  Of specific interest to this thesis, 
signaling proteins like cytokines and chemokines are also powerful regulators of cell fate.  One 
such signaling protein, the cytokine transforming growth factor β (TGFβ), plays a role in 
directing numerous cellular processes, including proliferation, homeostasis, and differentiation.  
Signaling proteins interact with both cells and the ECM in native tissues, where the ECM can 
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sequester growth factors via electrostatic affinity interactions, preserving protein bioactivity and 
stability1. 
 There is much interest, then, in methods to recapitulate such biological signaling capacity 
in PEG scaffold platforms, to improve the basic understanding of biological processes, as well as 
to accelerate and improve healing.  Towards that goal, this thesis pursues two general aims: i) the 
characterization of bioactive protein recovery following exposure to chain- and step-growth 
photopolymerizations and ii) the use of such reactions to covalently tether bioactive proteins into 
polymeric biomaterial platforms and study their influence on cell function. 
 Related to the first of these aims, we investigate the role that radically mediated 
polymerization reactions play in protein deactivation and loss of function, and characterize 
methods to ameliorate this damage.  These polymerization reactions enjoy wide use as a method 
for protein encapsulation in polymeric matrices.  By forming an encapsulating matrix in-situ, 
through the inclusion of protein in monomer solutions, the total protein payload can be precisely 
controlled.  One drawback of this approach, however, is the potential for loss of protein function, 
due to side reactions between monomer species and protein.   
 We hypothesize that this protein damage can be ameliorated in two ways.  First, since 
affinity ligands bind their target proteins to form a ligand-protein complex, this binding event 
may shield the protein from some radical-mediated damage during polymerization.  Secondly, 
we systematically study the role that the radical mechanism of polymerization itself can play in 
loss of protein function, by comparing relative bioactivity changes after exposure to chain- and 
step-growth reactions.  The following specific aims are proposed to test this two-fold hypothesis: 
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Specific Aim 1:  Examine the protective effect of affinity peptides on TGFβ  bioactivity 
during photoencapsulation in poly(ethylene glycol) diacrylate hydrogels. 
 We investigate the role that affinity peptides can play in the recovery of the cytokine 
transforming growth factor β (TGFβ) encapsulated in PEG diacrylate (PEGDA) hydrogels. 
Profiles of TGFβ release are generated from hydrogels composed of various molecular weights 
of end-functionalized linear PEG acrylate species.  The photoinitiated chain-growth reaction 
used to form these hydrogels can be modeled using solution polymerizations of 
monofunctionalized PEG acrylate species.  Using this approach, TGFβ recovery is characterized 
and related to polymerization conditions using both ELISA and bioactivity assays.  Peptides with 
reported affinity for TGFβ are synthesized, and their binding affinity confirmed with surface 
plasmon resonance.  Affinity peptides are then included in monomer solutions at varying peptide 
to protein ratios, and shown to increase the amount of bioactive TGFβ recovered when the 
cytokine is photoencapsulated in PEG hydrogels.   
 
Specific Aim 2:  Characterize and compare the recovery of bioactive protein from 
photoinitiated chain- and step-growth radical photopolymerization reactions. 
 Since we hypothesize that protein damage will correlate with radical concentrations 
during hydrogel evolution and protein entrapment, the effects of the radical polymerization 
mechanism on protein bioactivity was studied using a model protein, lysozyme.  First, 
photopolymerization conditions for hydrogel formation via acrylate chain-growth and thiol-ene 
step-growth are characterized.  Next, the effect of photogenerated radicals on lysozyme 
bioactivity is detailed, using the initiator lithium acylphosphinate (LAP).  Protein damage is 
quantified for multiple initiator concentrations and light intensities, and then plotted as a function 
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of total primary radical generation.  Non-crosslinking solution polymerizations are then used to 
measure the relative bioactivity loss of enzyme exposed to chain- and step-growth radical 
reactions, and protein damage is correlated to total photogenerated primary radicals.  This 
approach is then used to characterize recovery of bioactive lysozyme and TGFβ following 
exposure to chain- and step-growth reactions, using polymerization conditions determined for 
hydrogel formation.  Protein loss-of-function is further characterized for the thiol-ene reaction, 
for various initiator concentrations and light intensities, and protein destruction is correlated to 
total number of photogenerated primary radicals.  Lastly, we demonstrate the translation and 
utility of this approach by studying the recovery of bioactive TGFβ from cross-linked thiol-ene 
hydrogels. 
 
 Related to the second general aim of this thesis, we sought to create PEG hydrogels 
capable of presenting sustained protein signaling to cells, through the incorporation of a 
covalently tethered protein hydrogels.  Rather than a vehicle for soluble protein delivery, these 
platforms present a non-diffusing, conjugated protein molecule, detectable by cells seeded onto 
the gel surface and/or encapsulated in a three-dimensional culture model.  In-vivo, the 
extracellular matrix functions as a storage depot for a variety of growth factors, which are 
typically bound via electrostatic interaction with structural ECM proteins1.  Cytokines typically 
interact with receptors on a cell’s surface, rather than being internalized, and we hypothesize that 
covalently tethering proteins into a PEG hydrogel could not only recapitulate a physiologically 
similar growth factor presentation, but also contribute a sustained, persistent signal to 
encapsulated cells2. 
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 Many recent studies have demonstrated the feasibility of tethering bioactive proteins onto 
a variety of substrates3-5.  The reagent 2-iminothiolane can be used convert a primary amine, 
such at that present on a protein’s N-terminus, into a thiol.  Such thiolated proteins may then be 
incorporated into PEG based hydrogels, through the use of either a thiol-acrylate or thiol-ene 
reaction, to form a protein-functionalized biomaterial platform.  The resulting material provides 
not only a physical scaffold, but also one capable of presenting complex biological cues to cells 
in contact with the hydrogel.  Further, the use of covalently tethered proteins allows for 
experiments to test the effects of presentation of a more persistent growth factor signal.  To 
demonstrate the utility of tethered-protein hydrogel platforms to guide cell function, we propose 
to study the effect of tethered TGFβ on 1) promoting the chondrogenic differentiation of 
mesenchymal stem cells encapsulated in PEG hydrogels and 2) myofibroblastic activation of 
valvular interstitial cells seeded on PEG hydrogel substrates.  To test these hypotheses, the 
following specific aims are proposed: 
 
Specific Aim 3:  Investigate the use of tethered TGFβ  in promoting chondrogenic 
differentiation of human mesenchymal stem cells encapsulated in PEG diacrylate 
hydrogels. 
 TGFβ is a potent cytokine, capable of directing numerous cell functions, including the 
differentiation of human mesenchymal stem cells (hMSCs) down a chondrogenic pathway.  The 
wide cross-reactivity of TGFβ, coupled with its short half-live in-vivo, makes it an ideal model to 
demonstrate proof of concept for the utility of a tethered protein hydrogel platform.  TGFβ is 
thiolated using 2-iminothiolane, and bioactivity of thiolated TGFβ is compared to native TGFβ, 
using the PE.25 reporter cell line.  Thiolated TGFβ is then crosslinked into PEGDA hydrogels 
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using a thiol-acrylate mixed-mode reaction scheme.  The resulting hydrogels are assayed for 
detectable TGFβ using a modified three-dimensional gel ELISA approach, and bioactivity of 
tethered TGFβ is confirmed via encapsulation of PE.25 cells.  TGFβ presentation is shown to be 
tunable by varying the concentration of thiolated-TGFβ present in monomer solutions.  Finally, 
hMSCs are encapsulated in tethered TGFβ hydrogels, and we study how such tethered growth 
factor biomaterials promote the chondrogenic differentiation of hMSCs, as indicated by 
glycosaminoglycan (GAG) production and collagen type II secretion.  
 
Specific Aim 4: Use PEG hydrogel platforms to study biomechanical and biochemical 
factors contributing to myofibroblast activation of valvular interstitial cells. 
 Based upon the methods used in specific aim 3, aim 4 focuses on the covalent tethering 
of bioactive TGFβ into step-growth PEG hydrogel materials.  PEG norbornene-co-PEG thiol 
hydrogels are formed using a photoinitiated step-growth reaction.  Gels are synthesized through 
the solution polymerizations of thiol:ene mixtures; elasticity of the resulting PEG hydrogels is 
tuned by varying the ratio of ene:thiol in the monomer solutions.  After formation, gels are 
patterned with covalently tethered thiol-TGFβ using a sequential thiol-ene reaction.  Bioactive 
TGFβ surface density is confirmed via a modified surface ELISA and reporter cell assays.  Gels 
are seeded with valvular interstitial cells (VICs); VICs are seeded on low- (< 15 kPa substrate 
stiffness activation threshold), intermediate, and high (> 15 kPa) elasticity gels, and activation 
levels are characterized for control gels and those with surfaces patterned with TGFβ.  VIC 
activation is quantified by monitoring alpha smooth muscle actin, a hallmark of the activated 
myofibroblast phenotype.  Finally, TGFβ is photolithographically patterned onto PEG hydrogel 
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surfaces, which are subsequently used as a culture platform for VICs, demonstrating the utility of 
this platform for spatial control of cell activation. 
 Collectively, the objectives of this thesis are constructed to demonstrate the development 
of synthetic hydrogel platforms as tools for tailoring the cellular presentation of bioactive 
proteins.  This goal is realized through characterization of bioactive protein recovery from 
polymerization reactions and by covalently functionalizing a hydrogel scaffold with tethered 
proteins.  The resulting material platforms are capable of providing persistent, tailorable protein-
mitigated cell signaling in two- and three-dimensional	  culture.	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Chapter 3 
 
Affinity Peptides Protect Transforming Growth Factor Beta During Encapsulation in 
Poly(ethylene glycol) Hydrogels 
 
published in Biomacromolecules 12 (4), 1051 – 1057 (2011) 
 
 
3.1 Abstract  
 Transforming growth factor beta (TGFβ1) influences a host of cellular fates, including 
proliferation, migration, and differentiation.  Due to its short half-life and cross reactivity with a 
variety of cells, clinical application of TGFβ1 may benefit from a localized delivery strategy.  
Photoencapsulation of proteins in polymeric matrices offers such an opportunity; however, the 
reactions forming polymer networks often result in lowered protein bioactivity.  Here, PEG-
based gels formed from the chain polymerization of acrylated monomers were studied as a model 
system for TGFβ1 delivery.  Concentrations of acrylate group ranging from 0 to 50 mM and 
photopolymerization conditions were systematically altered to study their effects on TGFβ1 
bioactivity.  In addition, two peptide sequences, WSHW (KD = 8.20 nM) and KRIWFIPRSSWY 
(KD = 10.41 nM), that exhibit binding affinity for TGFβ1 were introduced into the monomer 
solution prior to encapsulation, to determine if affinity binders would increase the activity and 
release of the encapsulated growth factor.  The addition of affinity peptides enhanced the 
bioactivity of TGFβ1 in vitro from 1.3- to 2.9-fold, compared to hydrogels with no peptide.  
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Further, increasing the concentration of affinity peptides by a factor of 100 to 10,000 relative to 
the TGFβ1 concentration increased fractional recovery of the protein from PEG hydrogels. 
 
3.2 Introduction  
 Strategies to direct cellular functions in biomaterials via spatial and temporal delivery of 
proteins, such as growth factors, chemokines, and cytokines, are of growing interest in tissue 
engineering applications.  These biomacromolecules can control cell differentiation, 
proliferation, migration, and even apoptosis.1-6 However, dosing and targeting of proteins to 
specific cell populations can pose significant challenges.  For example, growth factors are 
eminently potent and can elicit a variety of cellular responses at picomolar concentrations.4  
Further, many factors are cross-reactive across a multitude of cells and tissue types and are 
known to have short half-lives in vivo.6  To overcome some of these limitations, a biomaterial 
delivery platform was explored to facilitate greater control over the bioactivity and availability of 
growth factors, particularly transforming growth factor beta (TGFβ1), delivered locally to 
targeted cell populations or tissues. 
 TGFβ1, a member of the TGF superfamily, regulates many cellular process including 
proliferation, differentiation, chemotaxis, and tumorigenesis.4  TGFβ1 is known to play a crucial 
role in promoting chondrogenic differentiation of human mesenchymal stem cells,7-10 guiding the 
organization of endothelial cells in angiogenesis11, and regulating the extracellular matrix 
production of valvular smooth muscle cells12. Since many cells express TGFβ1 receptors, a local 
delivery platform is often required for spatial and temporal control over its dosage.  One method 
for controlling the delivery of growth factors is through encapsulation in polymeric matrices, 
such as poly(ethylene glycol) (PEG).  PEG hydrogels have been used to deliver a variety of 
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growth factors; however, a great challenge facing PEG hydrogels crosslinked by chain growth 
polymerizations is the potential for irreversible protein damage.13   
 For many protein delivery applications, direct encapsulation of growth factors (i.e., 
through the inclusion of the target protein in the monomer precursor solution) is desirable due to 
its simplicity in preparation and a facile control of the total growth factor payload.  Photoinitiated 
reactions are commonly used in cell encapsulation schemes, due to their mild reaction conditions 
– specifically physiological pH, temperatures, and osmolarity.  While these characteristics render 
a photoinitiated polymerization system desirable for the formation of cell-laden hydrogels, they 
are known to create adverse reactions to protein therapeutics, which are usually unstable and can 
be easily denatured.  For example, growth factors present in the formation of hydrogels are 
susceptible to damage during the reaction, primarily due to the presence of highly reactive 
radical species14 generated by cleavage of photoinitiator species.  In addition to initiating 
polymerization reactions, these free radicals may undergo a number of non-specific side 
reactions with functional groups associated with amino acids, including phenols, thiols, and 
disulphides,15 leading to either direct conjugation of the growth factor to the polymer backbone 
or loss of protein conformation, and therefore, bioactivity.13  The development of an 
encapsulation scheme to ameliorate potential radical damage would, therefore, be desirable to 
enhance the efficacy of polymeric growth factor delivery platforms. 
 A number of polymeric materials have been utilized as protein delivery vehicles, 
including alginate16, collagen17, PLGA18, and PEG18.  Recent work demonstrates the use of novel 
polymeric materials incorporating affinity ligands for sustained protein release through mixed-
mode, thiol-acrylate polymerizations.19-21 These systems utilize ligands that non-covalently and 
reversibly interact with the target protein, with release being tuned by both diffusion and the 
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binding kinetics unique to the ligand-protein pair. Specific peptide-ligand systems, where the 
peptide ligand has affinity for a unique protein, have been shown effective for controlled release 
of bFGF19 and sequestration of MCP-120 and TNFα.21 Non-specific ligands such as heparin and 
alginate sulfate employ electrostatic affinity interactions present on numerous proteins;22 such 
ligands, when added to hydrogel systems have been utilized to govern release of many growth 
factors, including bFGF,23 NGF,24 VEGF,25,26 PDGF-BB,26,27 and TGFβ1.26-28 
 We hypothesized that the presence of free radicals generated during photoinitiated 
polymerizations would induce TGFβ1 structural and functional damage, and that the inclusion of 
affinity binding peptides during photopolymerization could prevent some of this damage.  Using 
photocrosslinked PEG hydrogels as a platform, we systematically studied the influence of 
photopolymerization conditions on TGFβ1 bioactivity and availability.  Quantification of 
released TGFβ1 was determined by ELISA, while confirmation of TGFβ1 bioactivity was 
achieved via a TGF-receptor reporter cell line.  Further, we analyzed the binding affinity of the 
TGFβ1 peptide ligands, Trp-Ser-His-Trp29 and Lys-Arg-Ile-Trp-Phe-Ile-Pro-Arg-Ser-Ser-Trp-
Tyr,30 using surface plasmon resonance studies.  These affinity peptides were included in 
monomer solutions during photoencapsulation of TGFβ1, and the enhancement of TGFβ1 
recovery from photopolymerized PEG hydrogels was examined.  The dose dependence of the 
peptide: TGFβ1 ratio on protein recovery and bioavailability from PEG hydrogels was also 
studied and quantified for both affinity sequences.     
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3.3 Materials and Methods 
 
Materials 
 All chemicals were purchased from Sigma-Aldrich unless otherwise noted. 
 
PEGDA synthesis 
 Poly(ethylene glycol) diacrylate (PEGDA) monomers were prepared as previously 
described.18  Briefly, hydroxyl-terminated poly(ethylene glycol) (Mn = 4600, 6000, or 10,000 Da) 
was reacted with acryloyl chloride in the presence of triethylamine under argon for overnight.  
The product solution was filtered through neutral alumina oxide and stirred for 2 hours in sodium 
carbonate.  After an additional filtering step, excess toluene was removed under reduced pressure 
and subsequently precipitated into cold ethyl ether.  1HNMR revealed a degree of acrylation of at 
least 95% for all material used in this study. 
 
Solid phase peptide synthesis 
 All peptides were synthesized using a solid phase peptide synthesizer (Applied 
Biosystems 433A) and standard Fmoc chemistry.  Peptide cleavage solution was formed by 
dissolving 250 mg dithiothreitol and 250 mg phenol in a solution of 95% trifluoroacetic acid 
(TFA), 2.5% triisopropylsilane (TIS), and 2.5% deionized water.  Synthesized peptides were 
cleaved in the solution for 2 hours.  Cleaved peptides were precipitated in cold ethyl ether and 
desiccated overnight, followed by reverse-phase HPLC (Waters Delta Prep 4000) purification.  
The collected fractions of purified peptides were identified by matrix-assisted laser 
desorption/ionization – time of flight (MALDI-TOF) mass spectrometry. 
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TGFβ1 photodestruction studies 
 Recombinant human TGFβ1 solutions (Peprotech) (final concentration: 2 nM) were 
prepared in PBS, in the presence of 1 mM lithium phenyl-2,4,6-trimethylbenzoylphosphinate31 
(LAP) initiator and varying concentrations of poly(ethylene glycol) monoacrylate (Monomer-
Polymer and Dajac Labs) (Mn = 2000 Da).  Solutions were exposed to UV light (Omnicure 365 
nm) at an intensity of 10 mW/cm2 for 3 minutes.  Following UV exposure, TGFβ1 solutions were 
analyzed with a Human/Mouse TGFβ1 ELISA kit (eBioscience) to determine the recovery of 
intact TGFβ1 
 
TGFβ1 release from PEG hydrogels 
 Human TGFβ1 at a final concentration of 25 nM was photo-encapsulated in 10 wt% PEG 
(Mn = 10,000 Da) hydrogels.  For affinity peptide formulations, TGFβ1 binding peptides WSHW 
or KRIWFIPRSSWY were also incorporated.  Peptides were included at a molar ratio, R, 
relative to TGFβ, equal to 100, 1,000, or 10,000.  Growth factor release studies were conducted 
in release buffer (1 mM EDTA and 0.05% BSA in PBS) in scintillation vials pre-treated with 
SigmaCote to reduce non-specific protein absorption on the wall of the vials.  Supernatants were 
collected at predetermined time points and replaced with fresh release buffer.  Concentrations of 
released TGFβ1 were determined by ELISA. 
 
TGFβ1 bioactivity assay 
 TGFβ1 bioactivity was confirmed with PE.25 cells stably transfected with a luciferase 
reporter gene.  The assay was performed as reported previously.32 Briefly, PE.25 cells were 
plated in 12 well plates (200,000 cells/well) and incubated in serum-free DMEM media.  
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PEGDA hydrogels  (Mn = 10,000 Da) encapsulated with 25 nM TGFβ1 were placed in co-culture 
with cells for 24 hours at 37° C, and 5% CO2.  Cells were lysed in lysis buffer (Promega) and 
frozen at -80°C for greater than 2 hours.  Lysate was centrifuged at 15,000 RPM at 4°C for 10 
minutes and supernatant collected and added to luciferase substrate (Promega).  Luminescence 
was measured using Perkins-Elmer 1420 spectrophotometer. 
 
Surface plasmon resonance binding studies 
 A Biacore 3000 instrument (GE Healthcare) and research grade carboxymethyldextran 
functionalized (CM5) biosencor chips (GE Healthcare) were used for all studies.  The flowcell 
surfaces were equilibrated in HBS-EP running buffer and preconditioned with NaOH, HCl, SDS 
and H3PO4.  Flowcell surfaces were activated with a solution of 0.25 M n-hydroxysuccinimide 
and 0.5 M N-ethyl-N’-(dimethylaminopropyl) carbodiimide hydrochloride, followed by injection 
of 6.2 mM N-Phenyldiethanalamine in 0.1 M borate buffer.  Flowcells were then injected with 
ligand-functionalized affinity peptides in acetate buffer, and all surfaces were then deactivated 
with a solution of l-cysteine/NaCl in 100 mM sodium formate buffer. 
 After allowing the flowcell surfaces to equilibrate with HBS-EP running buffer, solutions 
of varying concentrations of TGFβ1, diluted in HBS-EP buffer, were injected using kinetic 
analysis injection protocols through Biacontrol software.  All data was analyzed using Scrubber2 
software (BioLogic Software). 
 
Statistics 
 All data are reported as a mean ± s.e.m., based on three repeats per experimental 
condition, unless otherwise noted.   
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3.4 Results and Discussion 
Effect of network crosslinking density on TGFβ1 release 
 Varying crosslinking density (or mesh size) in hydrogel matrices provides a facile 
method to control solute diffusivity.  As an example, the mesh size of PEG hydrogels can be 
tailored by varying the molecular weight of PEGDA at a defined weight content.  Figure 1 shows 
fractional release of TGFβ1 encapsulated in 10-wt% PEG hydrogels of varying molecular 
weights.  Hydrogels of PEGDA 4,600 Da and 6,000 Da released less than 5% of the 
encapsulated protein over a two-day period, while 10 wt% PEGDA 10,000 Da gels released 
approximately 25% of the TGFβ1 payload over the same time frame.   To determine if the lower 
TGFβ1 release from PEGDA 4,600 Da and 6,000 Da gels was due to lower hydrogel mesh sizes 
that reduce apparent protein diffusivity, the mesh size of these gels was estimated from 
equilibrium swelling ratios using a modified Flory-Rehner method33 (Table 3.1): 
 
                              
Figure 3.1.  Fractional release of TGFβ1 as a function of time when entrapped in PEG gels 
formed from the solution polymerization of PEGDA monomers of varying molecular weight.  
All gels were formed from 10 wt% monomer systems.  The final network mesh size affects 
TGFβ1 release.  While PEG 4,600 and PEG 6,000 gels had no appreciable TGFβ1 release, PEG 
10,000 gels had 25% fractional release over 2 days.  
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Table 3.1.  Equilibrium swelling and calculated average mesh size of hydrogels formed from the 
solution polymerization of poly(ethylene glycol) diacrylate monomers of varying molecular 
weight.   
PEGDA Molecular 
Weight 
(Da) 
Mass Swelling 
Ratio, q 
Volumetric 
Swelling Ratio, Q 
Mesh Size, ξ, 
(Å) 
4,600 17 ± 2 18 ± 2 200 ± 20 
6,000 24 ± 1 25 ± 1 300 ± 20 
10,000 29 ± 2 31 ± 2 380 ± 40 
 
 While the hydrodynamic radius of TGFβ1 has not been reported in the literature, proteins 
of similar molecular weight, including chymotrypsinogen34 and enhanced green fluorescent 
protein35, have reported radii on the order of 28 – 35 Å.  However, since no appreciable amount 
of TGFβ1 encapsulated in PEGDA 4,600 and 6,000 was released over a two day period, mesh 
size was not likely the principal determinant of TGFβ1 release in this system.  In comparing the 
three hydrogel formulations used, the photoinitiator concentration and UV exposure conditions 
were identical, as were the monomer concentrations relative to the TGFβ1 concentration.  Due to 
the use of a constant weight/volume formulation, acrylate concentrations were not held constant 
(Table 2), and the effect of this factor on TGFβ1 release from the gels warranted further 
investigation, particularly since the rate of polymerization scales directly with the acrylate 
concentration to a first approximation. 
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Table 3.2. Calculated acrylate concentrations in formulations of various molecular weight 
PEGDAs at 10 wt%, the concentrations used to synthesize the hydrogel formulations. 	  
PEGDA Molecular Weight 
(Da) 
Acrylate Concentration at 10 wt% monomer 
(mM) 
4,600 43.5 
6,000 33.3 
10,000 20 
 
Effect of acrylate concentration on TGFβ1 recovery in solution 
 To characterize the effect of acrylate concentration on TGFβ1 recovery during 
photoinitiated reactions, a PEG monoacrylate (PEGMA) monomer was selected.  At low 
concentrations, similar to those used for hydrogel formation with the diacrylated PEG, 
monoacrylates do not form a crosslinked polymer when exposed to UV radiation in the presence 
of photoinitiators.   Photoinitiated radicals can propagate through the acrylate group, and 
polyacrylate kinetic chains are formed via a chain polymerization, but the polymer remains 
soluble.  This aspect makes PEGMA ideal for use in modeling the PEGDA – protein 
encapsulation reaction scheme13,36.  Proteins photoencapsulated in PEGDA may be covalently 
conjugated to the polymer, resulting in a loss of soluble protein in solution.  Alternatively, 
irradiated solutions of PEGMA and TGFβ1 may lead to radical mediated damage through chain 
transfer, and the solutions can be subsequently assayed for protein concentration or bioactivity.  
Reductions in either factor are attributed to the effects of reaction conditions. 
 Solutions of TGFβ1 and photoinitiator, with varying concentrations of PEGMA, were 
exposed to UV dosages identical to that used for photoencapsulation with diacrylate PEGDA.  
The influence of the polymerization conditions on TGFβ1 recovery after UV exposure was tested 
via ELISA on diluted solution samples, which showed increased growth factor recovery with 
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increasing acrylate concentration.  Maximum post-irradiation recovery of TGFβ1 greater than 
90% was found for acrylate concentrations above 40 mM (Figure 3.2A). TGFβ1 recovery data 
via ELISA (Figure 3.2a) supports results previously published on the so called “protective 
effect” that increasing monomer concentrations afford proteins13.  
 
Figure 3.2.  TGFβ1 recovery from photopolymerized acrylate solutions. (a) In non-gelling 
monoacrylate solutions, TGFβ1 recovery is highest at high acrylate concentrations, as measured 
by ELISA.  (b) Bioactivity assays across the same acrylate concentration range show a maximum 
at intermediate concentrations, as determined by reporter cell assay.  Error bars represent 
standard error (n=4). 
 
 Interestingly, bioactivity after UV exposure was maximized at 20 mM acrylate 
concentration, with lower activity at both higher and lower acrylate concentrations (Figure 3.2B).  
While loss of bioactivity of TGFβ1 at low acrylate concentration is consistent with data from the 
ELISA assays, reduced bioactivity for samples with high acrylate concentrations is not.  One 
explanation for this observation is potential PEGylation of the growth factor, resulting in a loss 
of bioactivity and increased hydrophilicity.  Direct detection of PEGylated TGFβ1 presents a 
challenge for traditional mass spectroscopic techniques, due to the biologically relevant 
nanomolar concentration range used.  This concentration is several orders of magnitude below 
the limit of detection for HPLC, NMR, GC, and MALDI methods.  PEGylated BMP-2 has been 
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characterized qualitatively using SDS-PAGE37, but this method is limited by low solubility of 
hydrophobic proteins, such as TGFβ1, in SDS solutions.  In the referenced work, PEGylation of 
BMP-2 was confirmed by SDS-PAGE at a protein concentration of 1 mg/mL, several orders of 
magnitude higher than that utilized for the present work.  For solution studies using PEG 
monoacrylate, any PEGylated growth factor remains in the reaction solution and is potentially 
detectable by ELISA techniques.  However, in diacrylate systems, PEGylated growth factors 
could be covalently conjugated to the hydrogel polymer.  Any conjugation would lead to 
significant reduction in the total fractional release of soluble, bioactive TGFβ1 from the polymer.  
This mechanism may explain, in part, the lower fractional release of TGFβ1 from PEGDA 4,600 
and PEGDA 6,000 hydrogels.   
Surface plasmon resonance studies confirm TGFβ1:peptide affinity 
 Affinity peptides have previously been used to successfully control the release of 
encapsulated proteins.18  Further, a small soluble affinity ligand has been previously used to 
protect photoencapsulated bovine serum albumin in PEG hydrogels.36  Here, we aimed to test 
whether inclusion of affinity peptides in monomer solutions could help protect proteins from 
radical mediated damage and/or conjugation during photoencapsulation reactions.  First, surface 
plasmon resonance (SPR) was used to characterize the binding affinity between each peptide 
sequence and TGFβ1.  SPR technology allows precise, label-free measurement of the formation 
of affinity-binding complexes between two interacting macomolecules38 and provides a useful 
way to analyze the affinity interactions between peptides and TGFβ1.  Two reported TGFβ1 
binding peptides were synthesized with a terminal cysteine separated from the binding sequence 
by two glycine spacers (CGGWSHW29 and CGGKRIWFIRPSSWY30) then covalently linked to 
a dextran-functionalized SPR flowcell surface using standard ligand-thiol coupling chemistry.  
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After equilibrating the chip in HBS-EP running buffer, TGFβ1 solutions of varying 
concentration, from 5 nM to 100 nM, were injected across flow cells, and the normalized 
response, proportional to the amount of peptide: TGFβ1 complex formed on the chip surface, is 
reported in Figure 3.3.   
 
Figure 3.3.  SPR sensorgrams for TGFβ1 injection over surfaces functionalized with immobilized 
peptides, CGGWSHW (a) and (b) CGGKRIWFIPRSSWY.   TGFβ1 was injected at 100, 50, 20, 
10, 5, and 0 nM in HBS-EP buffer at a flowrate of 50 µL/min.  Sensorgrams represent average 
signal for three injections. 
 
 Both the WSHW (Figure 3.3a) and KRIWFIPRSSWY (Figure 3.3b) functionalized 
flowcells exhibit the formation of affinity complexes with TGFβ1, and show binding in a dose-
dependent manner, confirming peptide: TGFβ1 affinity interaction.  Analysis of the association 
and dissociation regimes of the sensogram yielded kd, the peptide:TGFβ1 dissociation rate 
constants, and KD, equilibrium dissociation constants as shown in Table 3.3.  Each peptide 
sequence was found to have affinity binding capacity for TGFβ1 in the nanomolar range, 
qualifying each as a strong binder; however, the KD values for the two peptides do not differ 
significantly. 
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Table 3.3.  Affinity peptide:TGFβ1 kinetic parameters calculated from SPR analysis.  
Peptide Sequence kd x 104 (s-1) KD 
CGGWSHW 9.85 8.20 
CGGKRIWFIPRSSWY 8.22 10.41 
 
Affinity peptides do not inhibit bioavailability of TGFβ1 
 After SPR confirmation of peptide TGFβ1 affinity, an inhibition study was conducted to 
determine if peptides incubated with TGFβ1 would interfere with extracellular TGF receptors, 
preventing growth factor signaling.  The WSHW and KRIWFIPRSSWY sequences were 
originally reported as TGFβ1 inhibitors, but inhibition was demonstrated through growth factor 
pull-down studies, where solutions of growth factor are incubated with peptide tethered to a solid 
phase resin.  A bioactivity assay was required to investigate whether soluble peptides, complexed 
to TGFβ1 in solution, would interfere with TGF receptor signaling.  PE.25 cells, transfected with 
a luciferase reporter gene for SMAD signaling, were incubated with solutions of WSHW, 
KRIWFIPRSSWY, and TGFβ1 (Figure 3.4).  At a 10,000 molar excess and a peptide with a 
nanomolar dissociation constant, over 99% of the growth factor in solution will exist in the 
peptide:TGFβ1 affinity complex.  Luciferase activity of the cell lysate was insignificant in 
TGFβ1- conditions for both peptide solutions and a control, indicating affinity peptides are 
incapable of binding TGFβ1 receptors.  Luciferase activity of TGFβ1+ solutions was three orders 
of magnitude greater than that of respective TGFβ1- solutions, with no statistical difference 
between the activity of the peptide solutions and that of the control media.  Thus, the 
peptide:TGFβ1 affinity complex does not inhibit the growth factor receptor signaling, and TGFβ1 
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incubated with peptides in monomer solutions retains its bioactivity in the absence of 
photoencapsulation.   
 
Figure 3.4.  Affinity binding peptides WSHW or KRIWFIPRSSWY do not inhibit TGFβ1 
receptor signaling in media supplemented with TGFβ1, and peptides do not ellicit a response 
from PE.25 cells in TGFβ1 deficient media.   Error bars represent standard error (n=4). 
 
Soluble affinity peptides protect TGFβ1 during UV exposure 
 To further explore the effect of soluble peptides on protecting TGFβ1 during 
photopolymerization reactions, a monoacrylate solution study was employed, similar to that 
previously described.  Solutions of PEGMA (Mn = 2,000), photoinitiator, and TGFβ1 were 
exposed to UV radiation, and subsequently assayed via ELISA for TGFβ1 concentration, as were 
solutions containing WSHW or KRIWFIPRSSWY (R=1,000) (Figure 3.5).  For PEGMA 
solution exposed to UV radiation in the absence of affinity peptides, TGFβ1 recovery was 75% 
of the pre-exposure concentration, while solutions including WSHW or KRIWFIPRSSWY 
peptides had recovery of approximately 100%, and not significantly different from non-UV 
exposure condition (t-test, p < 0.05.)  These results confirm affinity peptides offer a protective 
effect for the encapsulated proteins during photopolymerization reactions.  Further, the inclusion 
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of these affinity peptides in monomer solutions should presumably increase the total fractional 
release of encapsulated growth factor from PEGDA hydrogels, as their presence in acrylate 
solutions provides an increase in recoverable TGFβ1. 
 
Figure 3.5.  Affinity Peptides Protect TGFβ1 During Photoencapsulation.  Soluble affinity 
peptides, added to monomer solution of 20 mM PEG (Mn = 2,000 Da) monoacrylate and 
photoinitiator, increase the amount of recovered TGFβ1 after UV exposure.  * indicates p<0.05 
(n=4) for each peptide concentration, relative to solution containing no peptide.   Error bars 
represent standard error (n=4). 
 
Affinity peptides increase fractional release of encapsulated TGFβ1 
 To characterize the effect of affinity peptides on TGFβ1 release from PEG hydrogels, the 
growth factor was encapsulated in monomer solutions of PEGDA Mn = 10,000 with or without 
affinity peptides.  Control gels (no peptide) and affinity gels (WSHW or KRIWFIPRSSWY at 
R=1000), were monitored over a four-day time frame (Figure 3.6a).   
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Figure 3.6.  Affinity peptides increase release of encapsulated TGFβ1 from PEG (Mn = 10,000 
Da) hydrogels.  (a) Hydrogels encapsulated with TGFβ and affinity peptides (R=1000) show 
greater release than gels encapsulated with growth factor alone.  Error bars represent standard 
error (n=4).  (b) When peptides are encapsulated with TGFβ1 in hydrogels, a higher cellular 
response is seen at 24 hours, relative to hydrogels without TGFβ1 or those with TGFβ1 and no 
peptide.  * represents p<0.05 (n=4) relative to TGFβ1 positive gels with no affinity peptides. 
 
 Of the three conditions, control gels exhibited the lowest fractional release of growth 
factor, with only 12.7 ± 1.2% of the TGFβ1 payload released by day four.  Affinity peptide gels 
released a larger fraction of the encapsulated growth factor; WSHW gels released 30.4 ± 5.3% 
and KRIWFIPRSSWY gels with 60.3 ± 5.8% of encapsulated TGFβ1 over the same time 
interval.  Interestingly, the release from KRIWFIPRSSWY peptide gels is much greater than that 
of gels with WSHW, although the two peptides exhibit similar dissociation constants (Table 3.3).  
Since the two affinity peptides differ in size, the difference in fractional release between the two 
affinity systems may be partially attributable to changes in the solubility of the TGFβ1-peptide 
complex, relative to unbound growth factor.  However, since TGFβ1 consists of a 112 amino acid 
chain, and the affinity peptides are four or twelve amino acids, their impact on solubility is 
expected to be minor.  While SPR techniques quantify binding strength between TGFβ1 and a 
given peptide, the photoencapsulation reaction is complicated by the inclusion of PEGDA 
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monomer and initiator species.  To confirm that differences in release between 
KRIWFIPRSSWY and WSHW gels were not due to bulk material differences, the shear modulus 
was measured for equilibrium swollen PEGDA gels to elucidate any potential differences in the 
crosslinking density.  Rheometric data showed inclusion of either affinity peptide in monomer 
solution did not significantly affect the swollen shear modulus, G’, of the resulting polymer. 
Thus, increased TGFβ1 release from peptide gels was not attributed to bulk differences in 
hydrogel crosslinking density.  These results provide confirmation that affinity peptide sequences 
WSHW and KRIWFIPRSSWY increase the amount TGFβ1 recovered from PEGDA hydrogels.  
 The presence of soluble peptides (R=1000) in monomer solutions of TGFβ1 and PEGDA 
Mn = 10,000 also increased bioactive growth factor release over a 24 hour period, as seen in 
Figure 3.6b.  PE.25 cells incubated with control gels with no affinity peptide had luciferase 
activity twice that of negative control conditions (TGFβ1-), while cells co-cultured with gels 
encapsulated with WSHW (R=1000) had three times higher activity, and KRIWFIPRSSWY gels 
produced 5 times greater luciferase activity in the reporter cells.   This result correlates to the 
trend in amount of TGFβ1 released (as measured with ELISA) over the same 24-hour time frame 
in Figure 3.6a.  Soluble affinity peptides, when included in monomer solutions prior to 
polymerization, then are shown to increase the amount of bioactive TGFβ1 released from PEG 
hydrogels.  
 Further, fractional release of TGFβ1 was increased when the peptide concentration in the 
monomer formulation was increased (Figure 3.7).  The growth factor was encapsulated at 25 nM 
in PEDGA Mn = 10, 000 for all studies, and the relative molar ratio of soluble peptide:TGFβ1 
was varied from a low concentration of 2.5 µM (R = 100) to a maximum peptide concentration 
of 250 µM (R = 10,000).  Gels encapsulated with affinity peptides WSHW or KRIWFIPRSSWY 
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had the highest fractional release over a two-day timespan with a ratio of R = 10,000, and lower 
fractional release was observed at lower ratios.  At R = 10,000, the inclusion of the WSHW 
peptide resulted in 58.8 ± 4.8% recovery, while KRIWFIPRSSWY (R=10,000) gel exhibited 
complete release (115 ± 15.5%) of encapsulated TGFβ1 over a two day timespan.  In conjunction 
with the monoacrylate studies on TGFβ1 recovery, these findings indicate that the presence of 
affinity peptides can be used to increase the amount of soluble and bioactive TGFβ1 in 
encapsulated hydrogels, resulting in more predictable delivery and higher total fractional release.   
 
Figure 3.7.  Increased concentration of affinity peptides increases release of encapsulated TGFβ1 
from PEG (Mn = 10,000 Da) hydrogels.  For both a) WSHW and b) KRIWFIPRSSWY peptides, 
high concentrations of peptide (R=10,000) results in maximum release of encapsulated TGFβ1.  
For KRIWFIPRSSWY, 100% fractional release is achieved in 1 day at R=10,000, while R=100 
gels only released 6.4 ± 1% over a 2 day time span.  For WSHW gels, R=10,000 gels achieved 
58.8 ± 5% release in 2 days, while R=100 gels only released 10.6 ± 1% of their payload in the 
same time.  Error bars represent standard error (n=4). 
 
3.5 Conclusion 
 Conditions to maximize release of the human cytokine TGFβ1 from photopolymerized 
PEG diacrylate hydrogel encapsulation were studied systematically.  In solution studies, high 
acrylate concentration, greater than 20 mM, showed an increase in recoverable TGFβ1, but a 
lowered bioactivity via cell activity assays.  Inclusion of affinity binding peptide sequences in 
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monomer solutions, prior to photoencapsulation, allowed higher total release of TGFβ1 from 
PEG hydrogels, as well as increased bioactivity of released protein.  The inclusion of soluble 
peptides provides a facile method for increasing the net recovery of encapsulated TGFβ1 in 
applications demanding localized and sustained delivery, such as tissue regeneration and wound 
healing.  
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Chapter 4 
 
Thiol-ene photopolymerizations provide a facile method to encapsulate proteins and 
maintain their bioactivity 
 
published in Biomacromolecules 
 
 
4.1 Abstract 
 Photoinitiated polymerization remains a robust method for fabrication of hydrogels, as 
these reactions allow facile spatial and temporal control of gelation and high compatibility for 
encapsulation of cells and biologics.  The chain-growth reaction of macromolecular monomers, 
such as acrylated PEG and hyaluronan, is commonly used to form hydrogels, but there is 
growing interest in step-growth photopolymerizations, such as the thiol-ene “click” reaction, as 
an alternative.  Thiol-ene reactions are not susceptible to oxygen inhibition and rapidly form 
hydrogels using low initiator concentrations.  In this work, we characterize the differences in 
recovery of bioactive proteins when exposed to similar photoinitiation conditions during thiol-
ene versus acrylate polymerizations.  Following exposure to chain polymerization of acrylates, 
lysozyme bioactivity was approximately 50%; after step-growth thiol-ene reaction, lysozyme 
retained nearly 100% of its pre-reaction activity.  Bioactive protein recovery was enhanced 1000 
fold in the presence of a thiol-ene reaction, relative to recovery from solutions containing 
identical primary radical concentrations, but without the thiol-ene components.  When the 
cytokine TGFβ was encapsulated in PEG hydrogels formed via the thiol-ene reaction, full 
protein bioactivity was preserved. 
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4.2 Introduction 
 Poly(ethylene glycol) (PEG) is utilized for a number of biomaterial applications, 
including anti-thrombotic and anti-fouling surfaces1, 2, implantable medical devices3, 4, drug 
delivery3, 5-7, and three-dimensional cell scaffolds8-10.  The hydrophilic nature of PEG minimizes 
non-specific interactions with many biomacromolecules, providing a material platform that is 
highly resistant to protein adsorption11, 12.  PEG is easily modified with functional end groups 
that can be subsequently crosslinked to form covalently linked networks.  There is growing 
interest in the use of PEG hydrogels formed from such reactions, especially photoinitiated 
crosslinking reactions, that can be performed in the presence of cells or biomolecules in-situ.  In 
the case of cell encapsulation, a variety of cytocompatible photopolymerization conditions have 
been identified that proceed at physiological temperature and osmolarity13-16, but conditions for 
encapsulation of proteins while maintaining activity are more stringent17, 18.  
 A common approach to forming PEG hydrogels is the chain polymerization of 
multi(meth)acrylated PEG monomers.  This acryl homo-polymerization proceeds to high 
conversion in aqueous environments, with rapid gel formation and development of a network 
structure characteristic of radically mediated chain growth polymerizations19, 20.  Photoinitiation 
is often used to form PEG gels, which allows spatial and temporal control of the polymerization 
process.   Hydrogel formation using photoinitiated polymerization of (meth)acrylated PEG 
monomers is particularly favorable for the encapsulation of cells, proteins and other biologically 
relevant molecules, as this approach allows for cytocompatible reaction temperature and facile 
maintenance of sterile conditions14.  Furthermore, a number of water-soluble photoinitiating 
species are commercially available, and the reaction exhibits low cytotoxicity at the wavelengths 
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and light dosages typically required for hydrogel formation13, 14.  However, the 
photoencapsulation of proteins and biologics can be more challenging and appropriate reaction 
conditions more difficult to identify17, 18, 21, 22.  
 While robust, the use of a radically-mediated polymerizations poses additional challenges 
when forming hydrogels via solution polymerization of (meth)acrylated monomers.  For 
instance, radical mediated chain-growth polymerizations are susceptible to oxygen inhibition23-
25, which results in longer polymerization times and requires increased irradiation dosing.  
Further, when used for encapsulation of biomacromolecules, the increased radical generation, 
lifetime, and exposure time can lead to undesired side effects, namely damage of the 
encapsulant17, 18.  A number of amino acids have reported antioxidant potential, including 
tyrosine, tryptophan, and cysteine among others26, 27, although cysteine is typically present in an 
oxidized state in the form of disulphide bridges, which has a lowered antioxidant potential28.  
Radical transfer from propagating polymeric chains to biomacromolecules can result in changes 
to protein secondary and tertiary structure17, chain scission27, 29, or protein-polymer conjugation.  
Several approaches have been shown to ameliorate this protein damage in (meth)acrylate chain-
growth reactions.  For instance, higher concentrations of acrylate monomer are effective in 
protecting lysozyme during photoinitiated polymerization17, and peptide affinity ligands included 
in pre-polymer solutions protect the cytokine TGFβ during encapsulation in PEG diacrylate 
hydrogels18.  While much effort has focused on strategies to minimize damage to encapsulated 
biologics during photoinitiated radical polymerization of PEGs, we sought to investigate the 
potential benefits of using different PEG precursors that undergo a radical mediated 
photopolymerization. 
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 In particular, there is a growing interest in “click” based thiol-ene photopolymerization30-
33.  The thiol-ene reaction proceeds via a radical mediated mechanism, but by proper choice of 
the ene functionality, gel formation occurs via a step-growth mechanism.  As a result, even with 
similar photoinitiation conditions, the radical concentrations and lifetimes can be substantially 
different during the evolution of PEG gels formed via acrylate chain polymerization versus thiol-
ene step polymerizations.   For example, PEG functionalized with terminal norbornene groups 
and reacted with bis(thiol) crosslinkers has been successfully copolymerized through 
photoinitiation to create hydrogel platforms for a number of biomaterials applications, including 
encapsulation of fibroblasts,10 pancreatic beta cells34, human mesenchymal stem cells35, primary 
valvular interstitial cells36 and therapeutic proteins37.  The thiol-ene reaction involves two steps: 
first, an initiator radical is transferred to a thiol, creating a thiyl radical that propagates across a 
carbon-carbon double bond.  Second, the carbon-radical rapidly undergoes chain-transfer to a 
new thiol, regenerating the thiyl species and allowing for a cycle of coupling reactions that form 
the macroscopic network (Scheme 1B).  Relative to (meth)acrylate chain growth, the thiol-ene 
reaction is less susceptible to oxygen inhibition30,  and differs in both the reactivity of the 
propagating radical species and radical lifetime.  While many measurement of acryl radical 
concentrations during photopolymerization have been reported38-40, no such measurement has yet 
been published for thiol-ene polymerizations and it is often implied that part of the reason for 
this lack of quantification is the very low radical concentrations30.  Further, the rapid 
polymerization of thiol-norbornene crosslinked polymers at physiological conditions makes 
these monomer systems an excellent choice for many in-situ forming hydrogel applications.   
We speculated that the lower radical concentration and rapid polymerization of the thiol-
ene step-growth reaction might improve protein bioactivity during encapsulation.  In this work, 
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we systematically compare protein activity during photoinitiated polymerization of PEG 
precursors utilizing two polymerization schemes: (i) acrylate chain-growth and  (ii) thiol-ene 
step-growth reactions.  In both the cases, polymerizations are photoinitiated using a water-
soluble initiator, lithium acylphospinate (LAP), and conducted in the presence of two proteins, 
lysozyme and TGFβ, to study the protein bioactivity during these radically-mediated 
photopolymerizations.  We investigate loss in protein bioactivity as a result of exposure to 
photoinitiated radicals, and characterize the differences in bioactivity when acrylates versus 
thiol-ene functional groups are polymerized, using the same initial functional group 
concentrations.  We show that at high extents of reaction, the thiol-ene step-growth reaction 
affords significantly higher levels of recovery of bioactive protein relative to that observed 
following chain-growth acrylate homopolymerization.  We correlate loss of protein activity to 
the concentration of radicals generated, and show that, during a thiol-ene polymerization, protein 
activity is preserved over a much broader range of photopolymerization conditions. 
 
 
4.3 Experimental Section  
 
Materials 
 All chemicals were purchased from Sigma-Aldrich unless noted otherwise. 
 
Synthesis of 4-arm PEG norbornene 
 4-arm PEG norbornene (PEG-4-NB) was synthesized as detailed elsewhere10. Briefly, 5-
norbornene 2-carboxylic acid was added at 10x excess (basis: PEG hydroxyl groups) with 5x 
excess dicyclohexylcarbodiimide in dichloromethane, and the solution stirred for 30 minutes at 
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room temp.  Separately, 4-arm PEG (Mn 10,000) (JenKem USA) was dissolved in DCM, with 5x 
pyridine and 0.5x 4-(dimethylamino) pyridine (DMAP), and then added to the DCC/norbornene 
solution.  The reaction mixture was stirred overnight at room temperature under argon.  The 
product was precipitated into ice-cold ethyl ether, and subsequently washed using soxhlet 
extraction into ethyl ether. 
 
Synthesis of PEG diacrylate 
 Linear PEG diacrylate was synthesized as detailed previously41.  Briefly, PEG (Mn 4,600) 
was dissolved in toluene and reacted with 4x acryoyl chloride (basis: PEG hydroxyls) in the 
presence of 4x triethylamine.  The mixture was stirred at room temperature overnight under 
argon.  Product was washed in DCM and precipitated in cold ethyl ether. 
 
In-Situ Dynamic Rheology during Photopolymerization 
 Rheometrical measurements were carried out on an Ares TA rheometer using a parallel 
plate geometry.  Hydrogels were formed using 10 wt% solutions of PEG-4-NB (Mn 10,000) 
reacted with linear PEG dithiol (Sigma), or PEGDA (Mn 4,600) at atmospheric (non-purged) 
conditions.  Approximately 30 seconds after beginning measurement, UV light (λ = 365nm, Io = 
10 mW/cm2) was introduced to the monomer solutions through a quartz plate, and modulus 
measurements were recorded in situ at 10% strain, 100 rad/s.  These settings were used after 
confirming that they were within the linear range, using strain sweeps on monomer solutions and 
the final crosslinked polymer.  
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Lysozyme-monomer photopolymerization studies 
 All monomer solutions were prepared with lysozyme (Worthington Biochemical) at a 
concentration of 1 µM, and photopolymerization was initiated using an Omnicure lamp (λ = 365 
nm) under optically thin conditions (100 µL monomer/sample).  Non-gelling acrylate 
polymerizations were conducted using PEG monoacrylate (Mn=2,000) (Monomer-Polymer and 
Dajac Labs) at a concentration of 40 mM in PBS, with 1 mM LAP initiator.  Four-arm PEG 
norbornene (Mn=10,000) was reacted at 10 mM (40 mM norbornene) with a stoichiometric 
cysteine concentration to create a non-gelling thiol-ene monomer system.  Thiol-ene 
polymerization reactions were initiated with 0.1, 1, or 10 mM LAP.  Following 
photopolymerization, protein/polymer solutions were assayed for enzymatic activity as described 
below. 
 
Lysozyme bioactivity assay 
 Lysozyme from chicken embryo (Worthington Biochemical) was reconstituted at 50 
mg/mL in deionized water, and further diluted to an appropriate working range (150-450 U/mL) 
in deionized water.  The substrate micrococcus lysodeiktus (Worthington Biochemical) was 
reconstituted in deionized water at 0.6 – 1.0 mg/mL.  For measurements of native bioactivity, 
solutions of lysozyme and substrate were mixed at a 1:1 ratio and changes in absorbance at 450 
nm were measured on a Biotek Hybrid H1 spectrophotometer.  Changes in absorbance were 
plotted versus time and correlated to changes in relative bioactivity. 
 
TGFβ bioactivity assay 
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 TGFβ bioactivity was quantified as described elsewhere42, using a mink lung epithelial 
cell line (PE.25) permanently transfected with a luciferase reporter for SMAD2 gene activity 
such that the cells produce luciferase upon culture with bioactive TGFβ.  Briefly, PE.25 cells 
were plated in 24-well TCPS plates (100,000 cells/well) in serum-free DMEM and incubated 
overnight at 37° C, 5% CO2 prior to culture with monomer solutions.   
 Non-gelling monomer solutions were formulated using either PEG monoacrylate or PEG 
4-norbornene/cysteine (500 µL/sample).  Each monomer solution was prepared to yield 40 mM 
reactive group concentration and TGFβ (Peprotech) at 20 nM.  Photopolymerization was 
initiated using 1 mM LAP at Io = 10 mW/cm2 (λ = 365 nm) in a sterile hood.  Prior to and 
following photopolymerization, 100 µL of the protein/polymer solution was diluted 1:1000 in 
serum-free DMEM media, and PE.25 cells were cultured in such for 18 hours.  Cells were lysed 
and analyzed using Glo-Lysis reagents (Promega), and luciferase production was quantified 
using a Biotek Hybrid H1 spectrophotometer. 
 
Encapsulation and recovery of model proteins from crosslinked thiol-ene hydrogels 
 Monomer solutions were formulated with 1 mM LAP, 4-arm PEG norbornene and linear 
PEG dithiol (Mn=1,500).  Lysozyme, chymotrypsinogen (Worthingon Biochemical), collagenase 
3 (Worthington Biochemical), and bovine serum albumin were encapsulated at 100 µg/gel (gel 
volume = 50 µL), and human serum was encapsulated at 4% v/v (gel volume of 50 µL).  Gels 
were formed by exposing the solutions to Io = 10 mW/cm2 (λ = 365 nm) for 5 seconds, then 
immediately placed into 2 mL PBS.  After 24 hours incubation at 4°C, the supernatant was 
assayed for protein concentration using MicroBCA (Pierce) as per the manufacturer’s 
instructions. 
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Encapsulation and recovery of bioactive TGFβ from crosslinked thiol-ene hydrogels 
 A monomer solution of 4-arm PEG norbornene (Mn=10,000), linear PEG dithiol 
(Mn=2000), 1 mM LAP, and 20 nM TGFβ was used to form crosslinked PEG hydrogels.   100 
µL of this monomer solution was crosslinked by exposure to light (Io = 10 mW/cm2, λ = 365 nm) 
for 10 seconds and immediately placed in 10 mL serum-free medium.  Alternatively, 100 µL of a 
monomer solution with 1 mM LAP and 20 nM TGFβ was placed directly into 10 mL serum-free 
medium (in the absence of polymerization).  Both media were incubated overnight at 37°C, 5% 
CO2, and then incubated with PE.25 cells for 18 hours under sterile conditions.  The cells were 
lysed and analyzed for luciferase activity as described above. 
 
Statistical analysis 
 
 All data were plotted and analyzed using Graphpad Prism 5.0 software.  Error bars are 
plotted as standard error measurement for three replicate conditions, unless otherwise noted. 
 
4.4 Results and Discussion. 
 
Network formation of thiol-ene and acrylate hydrogels 
 
 To compare the formation of hydrogel networks prepared from acrylate and thiol-ene 
reactions on protein activity, some measure of the light dosage needed to completely react the 
monomer functional groups via the respective mechanisms was required.  While direct 
monitoring of functional group conversion with spectroscopic methods was difficult because of 
their dilute concentration, we found in-situ rheology under UV exposure to be a highly sensitive 
method to monitor shear modulus development during photopolymerization.  Others43-45 have 
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shown that the plateau in the modulus correlates well with approximate reaction times for 
complete photopolymerization of hydrogels.  Figure 1A shows a plot of shear modulus (G’) vs. 
reaction time for monomer solutions irradiated at Io = 10 mW/cm2 (λ = 365 nm).  Initial 
functional group concentrations for both acrylate and thiol-ene systems were 40 mM, 
corresponding to an approximate 10-wt% monomer solution.  The initial concentrations were set 
equal to make comparisons between the two systems, as both the reaction time and protein 
stability depend on the functional group concentration.  Both the polymerizations were 
photoinitiated with LAP at an initial concentration of 1 mM.  As observed in Figure 1a, the step-
growth thiol-ene reaction proceeds rapidly, achieving a shear modulus on the order of 10 kPa 
after less than 10 seconds of light exposure.   
 
 
Scheme 4.1.  Monomer and polymer structure.  A) PEG diacrylate, B) PEG 4-arm norbornene, 
C) PEG dithiol.  Upon polymerization,  PEG diacrylate forms a chain-growth network as 
depicted in (D), while the thiol-ene reaction forms a step growth network (E). 
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Figure 4.1. In-situ rheology during photopolymerization shows evolution of mechanical 
properties for hydrogels formed via chain-growth acrylate and step-growth thiol-ene 
polymerizations.  A) Hydrogel formation for polymerization initiated at 10 mW/cm2 (λ = 365 
nm), in the presence of 1 mM LAP.  For equal initial functional group concentrations (40 mM), 
the thiol-ene reaction reached a maximum shear modulus of 10 kPa in less than ten seconds.  B) 
For a constant thiol-ene initial functional group concentration of 40 mM, polymerization was 
initiated using an intensity of 10 mW/cm2 (λ = 365 nm) while the LAP initiator concentration 
was varied from 0.1 mM to 10 mM.  10 and 1 mM LAP concentrations promoted complete 
crosslinking in less than ten seconds, but the polymerization was much slower with only 0.1 mM 
initiator and required ~60 s of light exposure for complete gel formation. 
 
 In contrast, the diacrylate chain-growth reaction requires over 300 seconds of light 
exposure to asymptotically approach a maximum modulus value, although after 180 seconds the 
shear modulus was within ~95% of the polymer’s final G’ of approximately 10 kPa.  Further, a 
significant lag time in elastic modulus evolution was observed (i.e., ~30 seconds), and is likely 
attributable to oxygen inhibition of the acrylate reaction, which is negligible in thiol-ene 
reactions30, 46.  The need to generate more radicals to overcome inhibition can become 
problematic for radically sensitive applications like cell or protein encapsulation.  This is 
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noteworthy, as a hydrogel formed via the thiol-ene necessitates shorter polymerization times and 
therefore, fewer photoinitiated radical species are generated (Table 4.1).  
Table 4.1.  Radicals generated as a function of initiator concentration and exposure time 
for an intensity of Io=10 mW/cm2.  Total initiator radicals generated were calculated 
using exposure total times determined from in-situ rheology during photopolymerization 
and species balance on the initiator and initiator radicals generated47 
 
Functional Group [LAP], mM Time to reach 95% of G’max, (s)† 
Total initiator radicals 
generated, mM‡ 
Acrylate 1 180 1.82 
0.1 60 0.11 
1 5 0.13 Thiol-ene 
10 1 0.27 
† as measured using rheology during photopolymerization 
‡ as calculated using 
€ 
Ri =
2 fφ 'ελ
NAhν
Io[LAP]t , where f is initiator efficiency, Φ’ is the 
number of radicals formed per photon absorbed, ελ is the initiator molar absorbtivity at a 
given wavelength, Io is incident light intensity, NA is Avogadro’s number, h is Planck’s 
constant, and ν represents the frequency of initiating light.  The photoinitiator 
concentration [LAP] is represented as a function of exposure time. 
 
Since the thiol-ene reaction is very rapid at typical photoinitiator concentrations used to 
make PEG-acrylate gels, we next investigated the effect of LAP initiator concentration on the 
polymerization time required to form PEG hydrogels using the thiol-ene reaction.  By varying 
the LAP concentration used to photoinitiate the reaction at a constant light intensity (λ = 365 nm, 
Io = 10 mW/cm2), the total time required for reaching a maximum shear modulus can be tuned 
(Figure 1B).  At both 1 and 10 mM LAP concentration, the thiol-ene hydrogel forms rapidly, and 
in less than 10 seconds of UV exposure, G’ has reached a maximum of approximately 10 kPa.  
Only at the lowest initiator concentration tested, 0.1 mM LAP, does the thiol-ene polymerization 
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require significantly longer exposure times of 60 s.  Despite this longer exposure time, the 0.1 
mM LAP condition still generates a lower total number of radicals than the 1 and 10 mM LAP 
conditions (Table 4.1).  Interestingly, over three orders of magnitude in LAP concentration 
range, the thiol-ene reaction can be utilized to form hydrogels with lower irradiation doses than 
that required to form similar PEG diacrylate networks, suggesting the thiol-ene polymerization 
may be advantageous for encapsulation of proteins or cells with known radical susceptibility. 
 
Loss of protein bioactivity from initiator radical species 
 After determination of the timescale for development of hydrogel networks using acrylate 
and thiol-ene reactions, it was necessary to determine similar ranges for the timescale and light 
doses to observe radically-mediated protein damage.  Lysozyme, an enzyme that lyses the 
bacterial cell wall as part of the innate immune system, was used as a model for screening 
protein bioactivity under various reaction conditions.  Native lysozyme bioactivity was measured 
and subsequently used as a benchmark for relative comparison.  Solutions of lysozyme were then 
prepared including LAP at a concentrations of 0.1 and 1 mM and irradiated with UV light (λ = 
365 nm) at two intensities, 1 and 10 mW/cm2 respectively, for a total of 60 seconds.  Results are 
shown in Figure 4.2.  At the highest light intensity of 10 mW/cm2 (Figure 4.2A), protein 
inactivation was rapid.  
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Figure 4.2. Protein destruction via photo generated initiator radicals. Solutions of protein and 
LAP were exposed to light for various times and subsequently assayed for bioactivity relative to 
native protein.   A) Loss of bioactivity in the presence of 1 or 0.1 mM LAP, exposed to Io = 10 
mW/cm2 of 365 nm light for various times; B) Loss of bioactivity for identical exposure times, 
but at a lower light intensity of 1 mW/cm2.  C) Loss of protein activity data plotted versus total 
concentration of radicals generated, with a trendline added for visualization.  Loss of protein 
bioactivity was rapid above a critical radical concentration of ~0.002 mM.  
 
 In particular, for the 1 mM LAP condition, 15 seconds of light exposure resulted in 
complete loss of protein function.  Lowering the LAP concentration to 0.1 mM slowed this 
protein destruction; after 60 seconds of exposure, approximately 75% of activity was lost.  The 
total number of radicals generated can be further lowered by reducing the light intensity, as 
shown in Figure 4.2B.  As expected, when the incident light intensity is reduced to 1 mW/cm2, a 
LAP concentration of 1 mM results in 75% protein inactivation after 60 seconds of light 
exposure, since the radicals generated for this condition should be identical to that of Io = 10 
mW/cm2 at a LAP concentration of 0.1 mM.  For the mildest condition tested, Io = 1 mW/cm2, 
with LAP at 0.1 mM, 60 seconds of light dosage resulted in ~ 25% loss of protein function, 
signifying that at lower radical concentrations, lysozyme exhibits some functional stability.   
 In order to characterize this protein damage in terms of radicals generated, the four 
protein activity data sets were plotted as a function of total photoinitiated radicals generated in 
Figure 4.2C.  The loss of protein activity collapses along a characteristic sigmoidal curve, with a 
critical threshold of ~0.002 mM radicals.  Below this concentration, there is little to no loss of 
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lysozyme function.  Above this plateau concentration, relative protein bioactivity rapidly 
declines, and total loss of bioactivity is achieved above a concentration of ~ 0.5 mM radicals 
generated.  This is quite interesting to note, as the concentration of dissolved oxygen in acrylic 
monomer solutions has reported on the order of 0.5 – 2 mM48, 49.  One potential cause for this 0.5 
mM radical threshold is the formation of reactive oxygen species, effectively consuming primary 
photogenerated radical species to protein in-situ lysozyme. 
 
Protein damage in the presence of photoinitiated acrylate and thiol-ene polymerizations 
 Next, solution polymerizations were used to study the loss of lysozyme bioactivity when 
the protein was present in-situ during radically-mediated acrylate and thiol-ene reactions.  Model 
formulations were selected to avoid gel formation and allow for ease of protein recovery.  Non-
gelling monomer systems were formulated at 40 mM functional group concentration, 
approximately equal to those used for hydrogel formation (Figure 4.1).  The acrylate chain-
growth reaction was modeled using PEG-monoacrylate, while the thiol-ene reaction was 
characterized using 4-arm PEG norbornene in conjunction with cysteine, a mono-functional 
thiol.  Relative protein bioactivity was measured for monomer/protein systems with no UV 
exposure, and compared to that of a native protein solution (Figure 4.3A.)   Both acrylate and 
thiol-ene monomer solutions, each with a LAP concentration of 1 mM, were then exposed to 
light (Io = 10 mW/cm2, λ = 365 nm,.)  Exposure times from Table 1 were used, in order to mimic 
the total number of radical generated during photoinitiation that are required for full network 
development of the target hydrogel formulations.  It should be noted that these solutions were 
exposed to light in optically thin conditions, and that for 365 nm light at Io = 10 mWcm2, more 
than 180 seconds are required to completely consume the initial LAP (supplemental 
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information).  Lysozyme exposed to acrylate chain-growth (180 seconds) exhibits a 50% 
reduction in bioactivity, relative to a non-irradiated monomer solution.  This result agrees well 
with previously published work17, 18 showing a “functional group protective effect.”  Namely, the 
higher concentration of reactive groups relative to protein concentration, typically a difference of 
several orders of magnitude, provides limited protection to proteins present in-situ during 
polymerization.   
 
Figure 4.3. Loss of protein bioactivity upon exposure to photoinitiated radical species. Solutions 
of monomer, protein and LAP (1 mM) were assayed for bioactivity before and after exposure to 
light at Io = 10 mW/cm2 (λ = 365 nm).  Acrylate and thiol-ene monomers, both at 40 mM 
functional group concentrations, were irradiated based on exposure times required for full shear 
modulus development.  A) For the acrylate reaction (180 s), lysozyme destruction is 
approximately 50%, while the thiol-ene step-growth reaction (10 s) preserves 100% of protein 
activity. Results are presented as average activity ± s.e.m. (n=5). B) After exposure to the 
acrylate chain-growth reaction, TGFβ loses all bioactivity, as measured by a reporter cell assay, 
while the thiol-ene step-growth reaction preserves 100% of protein activity.  Results are 
presented as average activity ± s.e.m. (n=4). 
 
 Interestingly, the thiol-ene reaction significantly increased the recovery of bioactive 
protein; after 10 seconds of light dosage, the relative lysozyme bioactivity was identical to that of 
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a solution receiving no light dose.  We postulate that this protein protection may be due to two 
factors.  First, the rapid conversion of the thiol-ene reaction allows for shorter light exposure 
times and a lower total number of radicals generated, as discussed previously.  Secondly, protein 
protection may be afforded due to the reactivity of the propagating radical species itself.  In a 
(meth)acrylate chain-growth reaction, a vinyl carbon radical is propagated, while in the thiol-ene 
step-growth mechanism, each propagation step results in both consumption and regeneration of a 
thiyl radical.  Our findings suggest that these thiyl radical species may be less destructive to 
proteins in-situ, or that the thiol-ene reaction is less promiscuous than the (meth)acryl chain-
growth mode of polymerization. 
To confirm protein protection results with the model protein lysozyme, we devised a 
study to measure the relative protection afforded by the thiol-ene and acrylate reactions using a 
more biologically significant protein.  The cytokine TGFβ is implicated in a number of cellular 
processes, and like many signaling proteins, exhibits bioactivity at very low concentrations, on 
the order of pico- to nanomolar50.  TGFβ was included in acrylate and thiol-ene monomer 
solutions, at a concentration of 20 nM.  As a control, TGFβ/monomers were diluted in culture 
medium and incubated with a reporter cell line (PE.25) for 18 hours.  Monomer/protein solutions 
were also exposed to light (Io=10 mW/cm2, λ=365nm) for times appropriate for gel crosslinking 
(Table 4.1), and subsequently diluted in culture medium.  Following incubation, cells were lysed 
and the lysate assayed for luciferase activity, a measure of bioactive TGFβ concentration in the 
medium (Figure 4.3B).  Non-irradiated solutions of acrylate and thiol-ene monomers had a 
similar luciferase activity, indicating that the monomers had no innate effect on the cell reporter 
assay.  Following polymerization, however, relative TGFβ bioactivity was distinctly higher for 
proteins in the thiol-ene monomer formulations, while TGFβ exposed to the acrylate chain-
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growth reaction retained no detectable bioactivity.  This finding is in contrast to the results 
reported in Figure 3, where the acrylate polymerization resulted in only 50% loss of lysozyme 
activity.  The higher damage could be due to differences in protein molecular weight (TGFβ is 
25 kDa, lysozyme is 15 kDa), susceptibility of the protein active site to radical damage, or 
concentration of protein in the photopolymerization.  Biologically relevant protein 
concentrations were chosen for this study, and for both lysozyme and TGFβ.  In either case, 
protein bioactivity was maintained at higher levels following exposure to thiol-ene reaction 
conditions. 
 
Characterizing protein protection afforded by the thiol-ene system 
To further characterize the ability to encapsulate proteins and maintain their activity 
using radically-mediated thiol-ene polymerizations, we next conducted in-situ 
protein/polymerization studies with varying concentration of a photoinitiator species, as this 
approach provides a facile method to study the effect of radical concentration on protein 
protection during a thiol-ene polymerization.  Solutions of protein and monomer were prepared, 
and the initiator LAP was included in the solutions at three different concentrations: 0.1, 1, and 
10 mM.  Protein solutions with no photoinitiator, both with and without thiol-ene monomer were 
also prepared, in order to determine loss of protein bioactivity, if any, due to irradiation alone.  
All protein solutions were exposed to light (λ = 365 nm, Io = 10 mW/cm2) for a total of 60 
seconds, and subsequently assayed for protein bioactivity.  Bioactivity results were normalized to 
a native protein sample and are presented in Figure 4.  Native protein, in the absence of thiol-ene 
monomer and LAP, maintained ~95% of pre-irradiation activity, a result that indicates light 
exposure alone has minimal negative effect on the function of lysozyme.  When thiol-ene 
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monomer is added to a protein solution, but no photoinitiator is present, bioactivity is ~100% 
following light exposure.  Radical damage, however, was determined to be the primary mode of 
protein inactivation, as seen in data for solutions containing LAP.  At the lowest initiator 
concentration tested, 0.1 mM, protein activity was maintained at approximately 100%; there was 
no significant difference in relative bioactivity between monomer solutions with 0 or 0.1 mM 
LAP concentration (p < 0.005).  At higher concentrations of LAP, however, protein protection 
provided by the thiol-ene polymerization became limited. 
 
Figure 4.4. Protection of in-situ protein bioactivity by thiol-ene monomer system.  Thiol-ene 
photopolymerizations were initiated with varying concentrations of LAP, while reactive 
functional group and protein concentrations were held constant.  Solutions were exposed to an 
identical light dosage (Io = 10 mW/cm2, λ = 365 nm) for 60 seconds, and subsequently assayed 
for protein bioactivity, relative to a native protein solution.  Results are presented as an average 
activity ± s.e.m. (n=5). 
 
For protein-monomer solutions formulated with 1 mM photoinitiator, ~75% of pre-
irradiation protein activity was maintained after polymerization; when the thiol-ene reaction was 
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initiated using 10 mM LAP, only 10% of protein activity remained following light exposure.  
This loss of protein protection by the thiol-ene system was somewhat expected, when 
considering the 60- second light dosage.  For polymerization at Io = 10 mWcm2 (λ = 365 nm), 60 
seconds far exceeds the time required to fully form a crosslinked hydrogel material, as reported 
in Table 4.1.  Based on this data, we hypothesized that the protection of proteins in-situ during a 
thiol-ene polymerization was due, in part, to the presence of unreacted monomer functional 
groups.  Thus, for the lower 0.1 mM LAP concentration, no loss of protein activity was observed 
over a 60 second exposure time, since this is the timescale over which polymerization occurs 
(i.e., the shear modulus is fully developed).  For the same functional group concentration and 
light dosage, both 1 and 10 mM LAP concentrations fully form a hydrogel in less than 10 
seconds.  Irradiation times beyond that necessary to reach complete polymerization would then 
result in radical generation in the absence of reactive groups, allowing proteins to be the primary 
target for radicals.  In practical terms, this reinforces the importance of limiting overexposure in 
photocuring applications.  Our hypothesis is supported by the data presented in Figure 4.4; 
however, to more fully characterize the timescale for protein destruction in the presence of a 
thiol-ene reaction, we designed a study to evaluate the light dosage conditions for in-situ protein-
polymer reactions and monitor resulting changes in bioactivity. 
 
Effects of varying light dosage on protein destruction during thiol-ene polymerization 
 Solutions were prepared with a constant concentration of thiol-ene functional groups (40 
mM) and lysozyme (1 µM), and these solutions were exposed to light (Io = 10 mWcm2, λ = 365 
nm) for a range of times from 0 to 180 seconds.  Following photopolymerization, relative 
bioactivity of the protein in the reaction mixture was assayed, and reported relative to a native 
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protein solution.  Results are plotted in Figure 4.5A.  While the lower LAP concentration of 0.1 
mM should exhibit the lowest protein destruction, results were somewhat unexpected.  Over a 
three-minute exposure time, there was no effective change in lysozyme bioactivity, although this 
time exceeds what is required for complete polymerization and network formation.  Likewise, 
when the thiol-ene polymerization was initiated with 10 mM LAP, solutions maintained high 
protein bioactivity.  After 180 seconds of exposure, protein in the thiol-ene monomer system 
retains only 30% of pre-irradiation activity.  These exposure times are much longer than that 
required to fully form a crosslinked hydrogel (Table 4.1), and this finding suggests that radical 
protection is afforded through a mechanism more complicated than that of simple functional 
group conversion.   
 
Figure 5. Loss in protein activity during photoinitiated radical generation with 0.1 and 10 mM 
LAP, following exposure to various light doses.  Non-gelling thiol-ene photopolymerizations 
were initiated with either 0.1 or 10 mM LAP, while functional group and protein concentrations 
were held constant.  Solutions were exposed to light (Io = 10 mW/cm2, λ = 365 nm) for 0, 2.5, 5, 
10, 20, 30, 60, 120, and 180 seconds, and subsequently assayed for protein bioactivity.  A) 
Protein bioactivity after light exposure is plotted for 0.1 and 10 mM initiator as a function of 
light exposure time.  B) Protein bioactivity data is plotted as a function of total radical 
concentration.  The line is included in order to guide the eye.  Plateau extends to a radical 
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concentration of 2.5 mM.  Results are plotted as average activity ± s.e.m. (n=4); error bars are 
smaller than the plotted symbols. 
 
 Figure 4.5B shows relative protein activity when exposed to both 0.1 mM and 10 mM 
LAP photoinitiation conditions, plotted as a function of total radical generation.  Results are 
plotted and fitted with a trendline, similar to the approach in Figure 4.2C with primary radicals.  
Interestingly, we observe that in the presence of thiol-ene polymerization, protein protection is 
much higher, as observe by modest losses in protein activity occurring below a critical total 
generated radical concentration of 2.5 mM.  This represents an increase of three orders of 
magnitude in activity relative to native protein solutions exposed to photoinitiator radicals in the 
absence of monomers (Figure 4.2C).  It is also noteworthy that this critical radical concentration 
for the onset in loss of protein activity is significantly higher than the radical number required to 
form hydrogels with 0.1, 1, or 10 mM LAP initiator. 
 
Table 4.2.  Protein recovery from crosslinked thiol-ene hydrogels.  Various proteins were 
encapsulated in thiol-ene hydrogels and release was monitored over a 24-hour period.  
Results are presented as average ± standard deviation (n=3) 
Protein Molecular Weight (kDa) % Recovery ± S.D. 
Lysozyme 15 80.5 ± 8.1 
Chymotrypsinogen 25 77.9 ± 2.6 
Collagenase 3 60 91.7 ± 14.7 
Bovine serum albumin 66 47.3 ± 4.2 
Human serum -- 79.7 ± 3.9 
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Figure 4.6. Encapsulation and recovery of bioactive TGFβ from thiol-ene hydrogels. Solutions of 
monomer, TGFβ and LAP (1 mM) were assayed for bioactivity before and after light dosage (Io 
= 10 mW/cm2, λ = 365 nm, 10 s).  Solutions of 4-arm PEG norbornene/PEG dithiol, both at 40 
mM functional group concentration, were added directly to culture medium (-UV) or were 
irradiated for times appropriate to fully form hydrogels (+UV).  For crosslinked samples, the 
resulting polymer was swollen overnight in culture medium and incubated with PE.25 reporter 
cells.  Cell lysate was assayed for luciferase activity to quantify bioactive TGFβ concentration. 
 
Encapsulation and recovery of proteins from crosslinked thiol-ene hydrogels 
 To demonstrate the utility of the thiol-ene reaction to recover proteins from PEG 
hydrogels, a number of proteins of various molecular weights were encapsulated in gels formed 
from 4-arm PEG norbornene and linear PEG dithiol.  LAP (1 mM) was used to initiate the 
photopolymerization (Io=10 mW/cm2, λ=365 nm) for 5 seconds (i.e., the time required to fully 
form the gel).  Protein-loaded gels were placed in PBS for 24 hours, at which time the protein 
concentration that diffused into the supernatant was quantified.  Recoveries of greater than 80% 
were measured for all encapsulated proteins, with the exception of bovine serum albumin (BSA).  
Interestingly, serum albumin has one non-oxidized cysteine residue that results in a free thiol51, 
which may explain its low recovery.   Finally, to access the bioactivity of proteins encapsulated 
using thiol-ene gel systems, TGFβ was studied. Specifically, TGFβ was included at 20 nM in a 
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monomer solution of 4-arm PEG norbornene and linear PEG dithiol using photopolymerization 
conditions that lead to high protein stability (Figure 4.3).  Non-photopolymerized monomer was 
added directly to culture medium.  For comparison, the monomer/protein formulation was also 
photopolymerized (Io = 10 mW/cm2, λ = 365 nm) for 10 seconds (i.e., the time required to fully 
form the gel (Table 4.1)), and the resulting hydrogel was added to the culture medium.  Both 
media samples were then incubated with the PE.25 reporter cell line overnight, and cell lysate 
was assayed for luciferase activity.  Results are plotted in Figure 4.6, showing that TGFβ 
encapsulated via a thiol-ene reaction had nearly identical bioactivity to that of growth factor that 
was simply in solution, but never exposed to the radical-mediated thiol-ene polymerization.  
 
4.5 Conclusions. 
 Hydrogels were formed via photopolymerization using acrylate chain-growth and thiol-
ene step growth mechanisms, and the appropriate light doses were confirmed using in-situ 
rheology under UV exposure.  Loss of protein bioactivity following exposure to photogenerated 
primary radicals was characterized using the enzyme lysozyme.  Non-gelling solution 
polymerizations were then used to study loss of protein function during exposure to acrylate and 
thiol-ene photopolymerization reactions, using lysozyme and the cytokine TGFβ.  While the 
acrylate reaction provided some marginal protection to in-situ protein, there was no loss of 
protein bioactivity following exposure to the thiol-ene reaction.  This may be due to the more 
rapid kinetics of the thiol-norbornene reaction or oxygen inhibition in the acrylate reaction, 
which required higher radical concentrations to proceed to completion.  When lysozyme, 
chymotrypsinogen, collagenase, bovine serum albumin, human serum, and TGFβ were 
encapsulated in crosslinked thiol-ene gels and subsequently released into PBS buffer, greater 
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than 80% recovery was observed.   Finally, TGFβ was encapsulated in PEG hydrogels formed 
via a thiol-ene reaction, and no statistically significant loss of bioactivity was detected relative to 
the non-encapsulated growth factor.  Photopolymerization reactions that provide rapid gelation at 
low radical concentrations are highly desirable for applications that seek to encapsulate sensitive 
payloads, such as proteins or cells.  Results of this study indicate that thiol-ene click reactions are 
capable of proceeding rapidly at low initiator concentrations with little to no impact on in-situ 
protein bioactivity. 
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Chapter 5 
 
Covalently tethered transforming growth factor beta in PEG hydrogels promotes 
chondrogenic differentiation of encapsulated human mesenchymal stem cells 
 
published in Drug Delivery and Translational Research 
 
 
5.1 Abstract  
 Methods to precisely control growth factor presentation in a local and sustained fashion 
are of increasing interest for a number of complex tissue engineering applications.  The cytokine 
transforming growth factor beta (TGFβ) plays a key role in promoting the chondrogenic 
differentiation of human mesenchymal stem cells (hMSCs).  Traditional chondrogenic 
approaches utilize soluble delivery, an approach with limited application for clinical translation.  
In this work, we introduce a reactive thiol onto TGFβ and covalently tether the growth factor 
into PEG hydrogels using a photoinitiated thiol-acrylate polymerization mechanism.  We 
demonstrate the bioactivity of thiolated TGFβ, before and after polymerization, using a SMAD2 
reporter cell line.  hMSCs were encapsulated in PEG hydrogels with and without tethered TGFβ, 
and subsequently assayed for glycosaminoglycan (GAG) and collagen-II production as indicators 
of chondrogenesis.  Over a 21-day time course, tethered TGFβ promoted chondrogenesis at 
levels similar to a positive control using solubly dosed growth factor.  These results provide 
evidence that tethered TGFβ materials can be successfully used to promote chondrogenic 
differentiation of MSCs. 
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5.2 Introduction  
There is growing interest in methods to sequester and present bioactive therapeutic 
proteins to cells immobilized in three-dimensional matrices, specifically for application in the 
areas of stem cell culture and regenerative medicine1.  Numerous biological processes are 
regulated through protein signaling.  For example, cytokines and chemokines are a particularly 
attractive target for tissue engineering applications, since these biomolecules are directly 
involved in controlling critical cell functions like proliferation, differentiation, and chemotaxis.  
Typically, these proteins are potent at concentrations as low as nano- to picomolar2-4, and many 
of them function via interaction with extracellular surface receptors5, which then regulate 
changes in gene expression.   Growth factors are commonly dosed solubly via culture media in 
vitro; however, in vivo, these proteins are sequestered in the extracellular matrix, and these 
sequestered factors are then available to nearby cells.  
 Hydrogel scaffolds are increasingly utilized to reconstruct and study such complex three-
dimensional interactions.  The cellular microenvironment plays a key role in providing diverse 
cues that direct cell function in-vivo6, 7.  The extracellular matrix itself provides not only a niche 
for cell attachment, but also acts as a storage depot for signaling proteins2, 6, 7, and there is 
growing interest in strategies that recapitulate aspects of these functionalities using synthetic 
hydrogel scaffolds.  Sequestered protein approaches also address practical implications for 
growth factor delivery.  Growth factors are typically cross-reactive with multiple cell types and 
are reported to have short serum half-lives3, limitations that often necessitate localized 
presentation, rather than systemic dosing.  Additionally, immobilizing such proteins allows 
control of total dose delivered, and can increase the safety and persistence of signaling.  Indeed, 
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immobilizing growth factors in a bioactive, physiologically relevant context is an important step 
towards clinical implementation for regenerative medicine as a whole.  Recently, a number of 
growth factors have been immobilized into synthetic substrates, including VEGF8, PDGF9, and 
TGFβ10-12, 37 and shown to maintain bioactivity while tethered.  Covalent incorporation of such 
potent cell-directing proteins into hydrogels suggests an attractive approach to design cell 
delivery scaffolds for locally directing and guiding cell properties important for tissue 
regeneration.  
 In this regard, we were particularly interested in modifying PEG hydrogels with proteins, 
as these systems are broadly explored for cell delivery applications13-17 and the low fouling 
properties of PEG render it useful for examining the effects of particular protein signals on 
encapsulated cell function.   One widely used approach for forming PEG hydrogels is through 
the photoinitiated chain polymerization of di(meth)acrylated PEG monomers.   
Photopolymerization allows for precise spatial and temporal control of polymerization and can 
be carried out at physiological temperature in aqueous conditions.  The resulting crosslinked 
PEG hydrogels have enjoyed wide utilization for encapsulation of numerous cells types with 
high cell survival reported following photoencapsulation18-20.  However, less explored is the 
mixed-mode thiol-acrylate photopolymerization14 that provides a facile method for incorporating 
thiol-functionalized molecules during polymerization of acrylate functional groups21.  Our group 
has successfully used this approach to incorporate a number of peptide functionalities into PEG 
hydrogels, including adhesive motifs21, 22, affinity binding ligands23, 24, and enzyme-cleavable 
peptides21, 25; however, proteins have been less explored.  We hypothesized that a thiolated 
growth factor, such as TGFβ, could be incorporated into PEG hydrogels via a thiol-acrylate 
photopolymerization while maintaining its activity and accessibility for cell-binding.  
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Specifically, we were interested in exploring how this method might be useful for locally 
promoting the chondrogenesis of human mesenchymal stem cells (hMSCs) in the absence of 
exogenously delivered TGFβ.    
 In this work, TGFβ was thiolated and covalently incorporated into PEG diacrylate 
hydrogels using a photoinitiated thiol-acrylate polymerization scheme.  We confirmed that 
thiolated TGFβ had bioactivity similar to that of the native, unmodified growth factor, using a 
cell reporter assay for SMAD2 signaling.  By varying the concentration of thiolated TGFβ in the 
monomer solution, the total growth factor concentration in the final gel was readily controlled, as 
determined by a modified surface ELISA.  Bioactivity of the tethered growth factor and the 
ability for it to signal encapsulated cells was further confirmed using the SMAD2 reporter cell 
line.  Finally, we demonstrate the potential of this material platform by encapsulating hMSCs in 
order to promote chondrogenic differentiation.  MSCs in tethered TGFβ hydrogels produced 
ECM proteins indicative of chondrogenic differentiation.  Namely, MSC cultured in gels with 
tethered TGFβ produced GAG and collagen-II at levels similar to or exceeding that of positive 
controls, where TGFβ was dosed solubly in the culture media.  We believe these results indicate 
the clinical potential of tethered growth factor biomaterial platforms as a cell delivery system for 
tissue engineering applications demanding tunable control of bioactive protein signals in a local 
and sustained manner. 
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5.3 Materials and Methods 
 
Cell culture and expansion 
 Human mesenchymal stem cells (hMSCs) were isolated from bone marrow aspirate 
(Lonza Biosciences) as detailed elsewhere26.  Cells were cultured in growth medium consisting 
of low glucose DMEM supplemented with 10 % fetal bovine serum, 1 µg/mL amphotericin B, 
50 U/mL penicillin, 50 µg/mL streptomycin and 20 µg/mL gentamicin.  Cultures were 
maintained at 5% CO2 and 37°C, and hMSCs were passaged up to three times prior to 
encapsulation studies. 
 PE.25 cells were cultured in growth medium identical to that used for hMSCs.  For 
analysis of TGFβ bioactivity, plated cells were cultured in serum-free DMEM supplemented 
with 1 µg/mL amphotericin B, 50 U/mL penicillin, 50 µg/mL streptomycin and 20 µg/mL 
gentamicin, augmented with either native (non-thiolated) or thiolated TGFβ at 5 ng/mL. 
 
Monomer synthesis 
 Poly(ethylene glycol) (Mn = 4,600) diacrylate (PEGDA) was synthesized as previously 
described24.  Briefly, poly(ethylene glycol) (PEG) was dissolved in toluene and reacted with 
acryoyl chloride in the presence of triethylamine overnight under argon.  The product was 
filtered through alumina oxide and neutralized with sodium carbonate.  The filtrate was then 
precipitated in cold ethyl ether.  Proton NMR was used to verify yield; typical functionalization 
for the PEG material used in this study was greater than 95%. 
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Growth factor incorporation into PEG hydrogels 
 2-iminothiolane (Pierce) was purchased and used to thiolate TGFβ (isoform 1) 
(Peprotech) according to the manufacturer’s recommendations.  Following the reaction, 
thiolated-TGFβ was aliquoted until used.  Thiolated-TGFβ was then reacted into PEG hydrogels 
via thiol-acrylate polymerization with the PEGDA monomer at concentrations of 0, 1, 10, or 100 
nM.  The hydrogels with the tethered growth factor were incubated overnight in PBS, and the 
TGFβ surface density was measured using a modified ELISA as described elsewhere12.   
 Briefly, gels were incubated overnight in a blocking solution of 1% BSA in PBS 
containing 0.05% Tween-20 (PBS-T).  Gels were washed 3x in PBS-T prior to incubation with a 
biotinylated anti-TGFβ antibody (eBioscience) for one hour at room temperature. Gels were 
washed 3x in PBS-T, and incubated with avidin-HRP (eBioscience) for 30 minutes, and washed 
3x in PBS-T.  After washing overnight in PBS-T, gels were incubated with 3, 3’, 5, 5’ 
tetramethylbenzidine substrate until color developed, at which time the reaction was stopped 
using 2N sulfuric acid.  The solutions were then measured for optical density at 450 nm using a 
Bioteck H1 spectrophotometer. 
 
Bioactivity of thiolated TGFβ 
 PE.25 cells were plated in 12-well plates at a density of 200,000 cells/well, then 
incubated with serum-free DMEM media augmented with 1 ng/mL native (non-thiolated) TGFβ 
(Peprotech) or thiolated TGFβ.  Cells were incubated overnight at 37°C, then analyzed using 
Glo-Lysis components from Promega. 
 Alternatively, PE.25 cells were encapsulated in PEG gels using a formulation of 10 wt% 
PEGDA, 1 mM LAP initiator, 1 mM CRGDS peptide and 0, 12.5 nM, 25 nM, or 50 nM 
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thiolated-TGFβ.  PE.25 cells were suspended at densities of 1, 5, 10, and 25 million cells/mL of 
solution, and cell-laden hydrogels were formed at a volume of 40 µL (O.D. ~ 5 mm, thickness ~ 
2 mm) using photoinitiation (Io~3.5 mW/cm2 at λ=365 nm) for 180 seconds.  Immediately 
following encapsulation, hydrogels were placed into growth medium in 48-well plates and 
incubated overnight at 37°C, 5% CO2.  Following incubation, hydrogels were placed in Glo-
Lysis buffer (Promega) for not less than 10 minutes and frozen at -70°C for greater than 2 hours. 
Lysate was incubated with luciferase substrate (Promega) and luminescence was monitored on a 
Biotek H1 Hybrid spectrophotometer. 
 
hMSC encapsulation in PEGDA hydrogels 
 hMSCs were encapsulated at 10 x 106  cells/mL in 10-wt% PEGDA (Mn=4,600) solution, 
with 2 mM CRGDS adhesive peptide and 1 mM LAP photoiniator.  Thiolated TGFβ 
concentrations of 0, 1, 10, or 100 nM were used to form tethered hydrogels.  Polymerization was 
initiated with light (I0=~3.5 mW/cm2, λ=365 nm) under sterile conditions to create 40 µL gels 
(O.D. ~ 5 mm, thickness ~ 2 mm), and cell-laden gels were immediately placed into 
experimental culture medium.  Growth medium (described previously) was used for a negative 
control, and chondrogenic medium (high glucose DMEM, 1 µg/mL amphotericin B, 50 U/mL 
penicillin, 50 µg/mL streptomycin, 20 µg/mL gentamicin, 100 nM dexamethasone, ITS+premix 
(6.25 µg/mL bovine insulin, 6.25 µg/mL transferrin, 6.25 µg/mL selenous acid, 5.33 µg/mL 
linoleic acid, 1.25 µg/mL bovine serum albumin), 100 µg/mL sodium pyruvate, 50 µg/mL 
ascorbic acid 2-phosphate) with 5 ng/mL soluble TGFβ was used as a positive control for 
chondrogenesis.  Hydrogels with tethered TGFβ (1, 10 or 100 nM) were cultured in 
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chondrogenic medium, but in the absence of soluble TGFβ added to the media.  Samples were 
harvested at day 0, 7, 14, and 21 for analysis of chondrogenesis. 
 
DNA quantification of encapsulated hMSCs 
 Immediately following photoencapsulation, cell-laden hydrogels (n=3) were placed into 
an enzymatic digest buffer (125 µg/mL papain (Worthington Biochemical), 10 mM cysteine) 
overnight at 60°C, then frozen prior to analysis.   Samples were similarly harvested at days 7 and 
14, and these solutions were then assayed for DNA content using a Picogreen assay (Invitrogen) 
to quantify changes in cell number between various culture conditions. 
 
Glycosaminoglycan production assay 
 Dimethyl methylene blue (DMMB) assay was used to quantify glycosaminoglycan 
(GAG) production in hydrogel scaffolds.  Cell-laden gels were harvested at pre-determined 
timepoints (day 0, 7, and 14) and incubated overnight at 60°C in 125 µg/mL papain, 10 mM 
cysteine.  Samples were then incubated with DMMB dye and analyzed for chondroitin sulfate 
content by measuring absorbance at 525 nm using a Biotek H1 spectrophotometer and 
comparing to a standard series for quantification. 
 
Histological Analyses 
 Samples were harvested after 20 days of culture and fixed in 4% formalin, 30% sucrose 
at 4°C for 48 hours.  Following fixing, gels were frozen and cryosectioned at 30 µm using a 
Leica CM1850 Cryostat.  Samples were stained for Safranin-O on a Leica Autostainer XL and 
imaged in bright field (40x) on a Nikon inverted microscope.  For immunostaining, sections were 
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blocked in 10% goat serum with 1% BSA, then incubated with antibodies for collagen type II 
(abcam) and CD105 (Sigma) for 2 hours.  Alexa Fluor conjugated secondary antibodies 
(Invitrogen) and DAPI were used to fluorescently label proteins of interest.  Images were 
collected on a Zeiss LSM710 scanning confocal microscope.  Quantification of collagen-II or 
CD-105 positive cells was performed on 10x images (3/sample, n=3 samples) by counting the 
number of cells positive for either collagen-II or CD-105, then normalizing to total cell nuclei 
using DAPI. 
 
Statistical analysis 
 
 All data were plotted and analyzed using Graphpad Prism 5.0 software.  Error bars are 
plotted as the standard deviation for three replicate conditions, unless otherwise noted.  
Statistical differences were calculated using a students t-test. 
 
5.4 Results and Discussion 
 
Activity of thiolated TGFβ in PEG hydrogels 
To introduce a functional group on native TGFβ for subsequent conjugation to PEG, the 
protein was thiolated via the reaction of 2-iminothiolane with primary amines, such as that found 
on the N-terminus.  During photopolymerization of PEG hydrogels, this thiol can be covalently 
tethered into the network via chain transfer from a propagating radical on a growing polyacrylate 
kinetic chain, creating a pendant protein presentation28, 29.  For confirmation of TGFβ activity 
following thiolation, a PE.25 cell assay was utilized.  This line has been permanently transfected 
with a luciferase reporter for SMAD2 activation, a indicator of TGFβ bioactivity27.  PE.25 cells 
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were plated and incubated in medium containing either native (non-thiolated) or thiolated TGFβ 
at identical concentrations.  Following an incubation period of 18 hours, the cells were lysed and 
assayed for luciferase activity, which represents relative TGFβ bioactivity (Figure 5.1A).  
Results indicate that thiolation with 2-iminothiolane did not significantly decrease the 
bioavailability of TGFβ (p<0.005).   
Thiolated TGFβ was then added to a PEGDA (Mn = 4,600) monomer (10-wt %) solution 
at 0, 12.5, 25, 50 or 100 nM, and the solutions were irradiated (Io ~ 3.5 mW/cm2, λ= 365 nm) for 
180 seconds.  The resulting hydrogels were then assayed for detectable TGFβ concentration 
using a modified surface ELISA12; results are presented in Figure 1B.  The ELISA confirms 
TGFβ incorporation into the gel, and results show a linear response for TGFβ in the 0-100 nM 
concentration range.  However, as this method only utilizes antibody recognition, further 
confirmation of bioactivity of the tethered TGFβ in the PEG hydrogel platform was required, 
using an encapsulation study with the PE.25 reporter cell line. 
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Figure 5.1.  TGFβ can be covalently incorporated into PEG hydrogels.  A) Results from a PE.25 
cell assay show that thiolated TGFβ provides identical bioactivity to that of native (non-
thiolated) growth factor. B) Surface ELISA results show detection of tethered TGFβ in PEG 
hydrogels, up to a concentration of 100 nM.  Monomer solutions containing 0, 12.5, 25, 50, or 
100 nM thiolated TGFβ were photopolymerized (Io = 3.5 mW/cm2, λ= 365 nm) and allowed to 
equilibrate in 1% BSA.  A surface ELISA showed a linear correlation between detectable TGFβ 
and its concentration in the initial monomer solution, providing a facile method to control the 
total protein payload.  * denotes values statistically non-zero (p < 0.05), and ** denotes statistical 
differences between concentrations (p < 0.05). Both data sets are presented as mean ± s.d. (n = 
5). 
 
 
Tethered TGFβ bioactivity in 3D culture 
 After confirming the tunability of TGFβ concentration in PEG hydrogels, we next wanted 
to investigate the bioactivity of TGFβ tethered in a 3D culture system using the thiol-acrylate 
polymerization reaction.  PEG diacrylate monomer (10-wt%) was formulated with varying 
concentrations of TGFβ: 0, 12.5, 25, and 50 nM.  Concurrently, the seeding density of PE.25 
cells was varied, with cells encapsulated at 1, 5, 10, or 25 million cells/mL.  This design was 
chosen for a number of reasons.  First, the effect of varying concentration of tethered TGFβ on 
cellular response was characterized, to provide insight into its bioactivity following the 
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photoinitiated thiol-acrylate reaction used to form these PEG hydrogels.  Secondly, this approach 
allowed us to test the bioavailability of the scaffold-tethered protein to cell binding and 
ultimately response.  While this PEG scaffold is non-degradable, this approach provides 
confirmation that tethered TGFβ is accessible to encapsulated cells.  This observation is similar 
to the effects of adhesive peptides incorporated into non-degradable gels, where embedded cell 
can bind with the tethered ligand in the immediate pericellular space.   Peptide signals often 
promote survival, but in a dose dependent manner and often with a threshold.  Thus, the amount 
of bioactive TGFβ assayed should be a function of both TGFβ concentration and cell density. 
Results are presented in Figure 5.2. 
For each tethered TGFβ concentration, an increased luciferase activity was observed over 
the lowest cell seeding densities of 1, 5, and 10 million cells/mL.  For gels formed with 12.5 nM 
TGFβ, there was no statistically significant increase in luciferase activity when the cell seeding 
density was further increased from 10 to 25 million cells/mL.  This result suggests that for the 
PEGDA hydrogels, at 10 MM cells/mL, tethered TGFβ is the limiting factor for signaling, 
possibly due to an excess cell-receptor concentration (i.e., a maximum cell density) or through 
limitations in receptor access to the tethered growth factor.  Increasing the concentration of 
tethered TGFβ for higher cell densities would be expected to result in increased levels of 
luciferase activity.  This hypothesis was confirmed for hydrogels containing 25 and 50 nM 
tethered TGFβ.  Luciferase activity was 7,800 AU for 25-nM hydrogels encapsulated at 10 MM 
cells/mL and increased to 12,600 AU at the higher 25 MM cells/mL seeding density.  Likewise, 
50-nM hydrogels had luciferase activity of 12,100 AU at 10 MM cells/mL, which increased to 
just over 21,800 AU at the higher density of 25 MM cells/mL.  Interestingly, in both the 25 nM 
and 50 nM TGFβ concentrations, increasing cell density by a factor of 2.5 resulted in a similar 
	   93	  
increase (165 - 180%) in bioactive TGFβ.  These results with the PE.25 cell line demonstrate the 
feasibility of presenting tethered TGFβ as a bioactive signal to encapsulated cells, so we next 
sought to devise a study to test the ability of these materials to promote a more biologically 
relevant and complex response – chondrogenic differentiation of mesenchymal stem cells 
(MSCs). 
 
Figure 5.2.  Tethered TGFβ hydrogels present a bioactive signal to encapsulated cells.  PE.25 
cells were encapsulated into hydrogels formed with 12.5, 25, or 50 nM tethered TGFβ.  Cells 
were encapsulated at densities of 1, 5, 10, or 25 million cells/mL.  For all TGFβ concentrations 
tested, increasing the cell density from 1 to 10 MM cells/mL produced increased luciferase 
activity, a measure of the bioactive TGFβ concentration detected by the cells.  Hydrogels with 
12.5 nM tethered TGFβ had no statistically significant increase in luciferase activity between 10 
and 25 MM cells/mL, indicating that the amount of available tethered growth factor is limiting.  
At higher TGFβ concentrations (25 and 50 nM), luciferase activity increased with increasing cell 
number.  For a given TGFβ concentration, t-test showed significant difference between all 
luciferase values except those indicated with *.  Results are presented as mean activity ± s.d. (n = 
5). 
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DNA quantification of hMSCs encapsulated in tethered TGFβ hydrogels 
 After confirming that tethered TGFβ maintained its bioactivity following 
photopolymerization, we then wanted to investigate whether such a platform could promote 
chondrogenic differentiation of encapsulated hMSCs.  Cells were encapsulated at a density of 10 
MM cells/mL in 10-wt% PEGDA hydrogels with 1 mM CRGDS peptide to promote integrin 
binding and survival.  Immediately following photopolymerization, gels were assayed for DNA 
content via a Picogreen assay, and subsequently tested through culture for 14 days.  Results are 
presented in Figure 5.3.  Cells cultured in growth medium showed little increase in DNA content 
over 14 days, agreeing with previous work on hMSC encapsulation26.  In contrast, samples in 
chondrogenic medium exhibited a two-fold increase in DNA content over the same time course.  
When tethered TGFβ was added to the hydrogel at the lowest concentration of 1 nM, DNA 
content also remained unchanged and approximated that of the profile of gels cultured in growth 
medium.  At the higher concentrations of 10 and 100 nM TGFβ, DNA content increased and was 
along the same order of magnitude as chondrogenic culture samples.  These finding suggested 
that in all cases, cell survival following photoencapsulation was robust, a finding confirmed via 
histological and immunostaining analyses in following sections. 
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Figure 5.3.  Viability of hMSCs encapsulated in tethered TGFβ hydrogels.  DNA content of cell-laden hydrogels 
was assayed over 14 days of culture, and used as a general correlative measure of cell viability.  Hydrogels cultured 
in growth medium (used as a negative control for chondrogenesis) maintained initial cell counts, as did those 
incorporating 1 nM tethered TGFβ.  Chondrogenic media samples (positive control) exhibited an increase in DNA 
of approximately 2-fold, while TGFβ tethered at 10 or 100 nM demonstrated similar increases in DNA content, 
suggesting high levels of viability of the encapsulated hMSCs.  Results are presented as mean ± s.e.m. (n = 3).  
 
GAG secretion of encapsulated hMSCs 
 Glycosaminoglycan (GAG) production is one key earlier indicator of a chondrocyte-like 
phenotype30-32.  Native cartilage is comprised primary of sulfated GAG chains and type II 
collagen.  A DMMB assay was used to quantify secreted GAGs immobilized in the PEG 
hydrogel scaffold, as previously described21, 22, 33.  Results are presented in Figure 5.4A, with 
GAG secretion normalized to DNA (µg ChSA/ng DNA).  For hydrogels cultured in growth 
medium, there was little to no measurable amount of GAGs.  Day 0 content (for all samples) was 
14.8 ± 5.6 µg/ng, and day 14 growth samples contained 13.2 ± 1.8 µg/ng.  As a positive control, 
MSC-laden hydrogels cultured in chondrogenic medium had a marked increase in GAG 
production; at day 14, chondrogenic samples contained 70.2 ± 5.6 µg/ng.  Interestingly, tethered 
TGFβ at 1 nM provided a minimal increase over growth media, as cell-laden hydrogels were 
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assayed to contain 22.4 ± 0.4 µg/ng at day 14.  However, at the same time point, both 10 nM 
(54.9 ± 1.1 µg/ng) and 100 nM (53.4 ± 10.7 µg/ng) had GAG production similar to that of the 
positive control, where TGFβ was delivered solubly.  At day 14, each tethered TGFβ gel 
condition resulted in a statistically significant amount of GAG production relative to that of the 
negative control (p < 0.01).  Noteworthy, however, is the total amount of growth factor delivered 
to encapsulated cells in this study.  In chondrogenic medium, TGFβ is added to the media at a 
concentration of 5 ng/mL (0.2 nM), which is a much lower concentration than used in the 
hydrogels (1 to 100 nM).  However, over 22 days of culture with media exchanges every 2 days, 
the total amount of TGFβ delivered in the soluble form is 55 ng/gel.  In contrast, incorporating 
tethered TGFβ at 100 nM required 100 ng/gel, while the 10 nM gels used only 10 ng growth 
factor/gel to achieve a similar level of chondrogenesis.  Further, tethering growth factors or other 
proteins into an implantable biomaterial provides a method to signal cells delivered in-vivo, and 
this approach could be readily used to present multiple protein signals to cells, even in various 
regions of a single material. 
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Figure 5.4.  Glycosaminoglycan production by hMSCs encapsulated in tethered TGFβ hydrogels.  
A) ChSA production was quantified on a per gel basis via the DMMB assay, and is a measure of 
cellular GAG production, indicative of chondrogenesis.  When TGFβ was tethered at 1 nM, 
GAG production was limited and similar in magnitude to that of hydrogels cultured in growth 
medium, which acts as a negative control condition for chondrogenesis.  At higher 
concentrations (10 and 100 nM) of tethered TGFβ, GAG production exceeded that of the 
positive control (chondrogenic media), where TGFβ was dosed solubly. B-E) Safranin-O 
staining shows GAG distribution in the pericellular space for chondrogenic media culture (C), as 
well at 10 (E) and 100 nM (F) tethered TGFβ gels.  Gels culture in growth media (B) and those 
with 1 nM tethered TGFβ (D) had negligible staining for GAGs.  Scale bar = 100 µm. 
 
 Histological analyses of MSC cultured in tethered TGFβ hydrogels for extended time 
periods provide a spatial representation of GAG deposition (Figure 5.4B).  Hydrogels were 
harvested at day 21, cryosectioned, and stained with Safranin-O, which stains GAGs red and 
counterstained with haematoxylin with stains nuclei blue/black.  Gels cultured in growth medium 
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had negligible red color surrounding nuclei, confirming data obtained from the DMMB assay.  
Likewise, gels incorporating 1 nM tethered TGFβ have a low level of proteoglycan content, 
observed by faint staining.  In contrast, hydrogels cultured in chondrogenic media had significant 
GAG deposition in the pericellular region and beyond, as did gels formed with either 10 or 100 
nM tethered TGFβ.  Since this hydrogel platform has no degradable crosslinks, there is limited 
interstitial space for deposition of secreted ECM and this leads to some of the observed spatial 
heterogeneity.  However, this data agrees with previously published work on GAG deposition for 
primary chondrocytes encapsulated in similar PEG-based materials34, 35. 
 
Collagen II production in tethered TGFβ hydrogels 
 Collagen type II secretion is another hallmark of chondrogenic differentiation of hMSCs, 
while expression of the CD-105 cell surface marker is often used as one of the characteristic 
markers for un-differentiated hMSC21, 32, 36.  To further characterize the role that tethered TGFβ 
plays in promoting later stages of chondrogenesis, cell-laden gels were harvested after 21 days of 
culture for immunostaining.  Samples were stained for type II collagen, CD-105, and DAPI to 
visualize cell nuclei.  Representative images are presented in Figure 5.  Growth samples express 
the CD-105 marker to a greater degree than any samples cultured in chondrogenic conditions 
(green in Figure 5.5), and only 2.2% ± 0.6% were positive for collagen-II.  Interestingly, while 1 
nM tethered TGFβ hydrogels did not produce appreciable amounts of GAGs (Figure 5.4), cells 
encapsulated in this gel formulation were negative for CD-105 staining, while 5.5% ± 0.7% of 
cells counted were positive for collagen-II, suggesting that the MSCs may be differentiating 
down other pathways.  Cells encapsulated in hydrogels formed with either 10 (84.0% ± 13.9%) 
or 100 nM (91.0% ± 0.2%) tethered TGFβ were largely positive for collagen-II production (red 
	   99	  
in Figure 5.5), similar to levels observed with the positive control (89.3% ± 7.2%), chondrogenic 
medium with soluble TGFβ.  
 
Figure 5.5.  Immunostaining shows collagen II (red) or CD-105 (green) production by hMSCs 
encapsulated in PEG hydrogels.  Nuclei are counterstained with DAPI (blue).  Growth samples 
were positive for CD-105, indicating non-differentiated cells.  Gels cultured in chondrogenic 
media with soluble TGFβ expressed little CD-105, but were positive for collagen-II, a hallmark 
of chondrogenic differentiation.  Cells cultured in hydrogels with tethered TGFβ at 1 nM, 10 nM, 
or 100 nM were all positive for collagen-II and negative for CD-105.  Scale bar = 200 µm.   
 
5.5 Conclusions 
 Thiolated TGFβ was shown to maintain its bioactivity, and a surface ELISA method was 
developed to confirm that TGFβ was detectable following covalent incorporation in PEGDA 
hydrogels.  PE.25 cells encapsulated in such tethered TGFβ hydrogels were used to confirm that 
tethered TGFβ maintained its bioactivity when presented in this fashion.  When hMSCs were 
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encapsulated in tethered TGFβ hydrogels, the tethered growth factor promoted chondrogenic 
differentiation at levels equal to or exceeding that of positive controls, where TGFβ was dosed 
solubly via culture medium.  Additionally, tethered TGFβ hydrogels utilized a lower total dosage 
to promote differentiation.  Collectively, these results demonstrate the feasibility of delivering 
bioactive protein signals in a three-dimensional culture platform to control stem cell fate, which 
may have further implications in the design of delivery vehicles for hMSCs to promote 
chondrogenesis and cartilage regeneration in vivo. 
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Chapter 6 
 
Surface patterning of bioactive TGFβ  to investigate microenvironmental factors 
influencing valvular interstitial cell activation 
 
in preparation 
 
 
6.1 Abstract 
 Valvular interstitial cells (VICs) comprise the primary population of cells found in heart 
valve tissue, and are responsible for tissue homeostasis and wound repair.  These cells can be 
activated into a myofibroblastic phenotype by changes in substrate elasticity or through 
transforming growth factor β (TGFβ) signaling, both of which can occur in response to injury or 
pathology.  While the role of these factors is commonly studied individually, less is understood 
about the competing or synergistic role they can play in VIC activation.  In this work, we form 
thiol-ene hydrogels with tunable elasticity (E = 3.5 – 23 kPa) to create activating and non-
activating substrates, and covalently tether TGFβ onto these gel surfaces using a secondary thiol-
ene photocoupling reaction.  TGFβ surface density is controlled by varying the thiolated TGFβ 
concentration in the patterning solution, across a range from 1 to 100 nM, and the resulting gel 
surfaces are characterized with both a surface ELISA and a cellular bioactivity assay.  VICs 
cultured on tethered TGFβ surfaces have increased levels of αSMA fiber formation relative to 
cultures on gels with no TGFβ.  Additionally, VICs cultured on tethered TGFβ gels with elastic 
moduli greater than ~12 kPa formed multicellular nodules, further indicating an increased level 
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of myofibroblastic cells.  These results demonstrate the utility of tethered TGFβ hydrogels to 
study the interplay between biochemical and biomechanical cues in regulating VIC phenotype. 
 
6.2 Introduction. 
 Valvular interstitial cells (VICs) are the main population of cells in the aortic heart valve, 
and are essential in the maintenance and repair of the heart valve leaflets’ extracellular matrix 
(ECM)1-6.  Upon valve injury, VICs can undergo transition from a quiescent fibroblast state into 
an activated, secretory myofibroblastic phenotype, which is able to proliferate6-8, produces 
increased levels of cytokines, including transforming growth factor β (TGFβ)6, 8, 9, and ECM3, 6-8, 
10, 11, and expresses the myofibroblast marker α-smooth muscle actin (αSMA)5, 6, 8, 11.  Following 
repair, this myofibroblast population is believed to then transition back to a quiescent state12.  
Prolonged activation of these cells can lead to pathological VIC behavior (i.e. osteogenic-like 
gene and collagen expression) pervading the entire leaflet, which can eventually lead to valve 
stenosis with subsequent loss of function5, 6, 13. 
 Multiple factors from the cellular microenvironment can play a role in regulating the 
activation of VICs.  One such factor, the cytokine TGFβ, influences a host of cellular activities, 
including proliferation14-16, differentiation14-16, immune response17, and ECM deposition18, 
among others.  While healthy heart valves maintain low levels of this protein, in stenotic valve 
samples, TGFβ is localized at high concentrations in calcific nodules19.  Alternatively, 
biomechanical properties of the valve tissue itself can also act as a trigger for a myofibroblast 
transition.  Native, healthy heart valve tissue has an elastic modulus on the order of ~7 kPa20, 
while stenotic valves are more stiff, with reports of calcified valve leaflets measured with E = 
32kPa21.   
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 Hydrogel cell scaffolds are emerging as powerful tools for studying such biochemical and 
biomechanical cues and their influence on cellular behavior.  PEG hydrogels can by synthesized 
via numerous cytocompatible chemistries to form culture platforms with highly tunable 
mechanical properties22-25.  As an example, our group has recently used these materials to 
explore the critical role that substrate stiffness plays in controlling the myofibroblast activation 
of VICs.  A threshold of ~15 kPa (E) has been demonstrated for VIC activation to αSMA fiber 
positive myofibroblasts26.  However, less understood is the competing or cooperative roles that 
biomechanical and biochemical cues play in VIC activation. 
 In this work, we utilize a thiol-ene “click” reaction to form PEG hydrogels with tunable 
elasticity as a platform for studying the complex interplay between biochemical and 
biomechanical factors influencing the activation of VICs to a myofibroblast phenotype.  Here, 
we use a 4-armed PEG (Mn = 10,000 Da) norbornene (PEG-4-NB) copolymerized with linear 
PEG bis(thiol) (Mn = 2,000 Da) to form a step-growth PEG hydrogel for VIC culture.  By 
varying the stoichiometric ratio of bis(thiol) crosslinker to PEG-4-NB, this platform can be 
readily tuned to provide gels with a range of crosslinking densities and resulting elasticities.  
Gels formed with a 0.67 thiol: norbornene ratio provide a soft substrate (~3.5 kPa) with minimal 
myofibroblast activation.  Increasing this ratio to 0.90 results in a substrate stiffness (~23 kPa) 
above the reported 15 kPa activation threshold for VIC activation26, while a thiol: ene ratio of 
0.75 produces an intermediate modulus (~11.5 kPa).   
 TGFβ is thiolated via reaction with 2-iminothiolane and subsequently tethered to 
hydrogel surfaces using a second photocoupling reaction.  The TGFβ-modified surfaces are 
characterized for relative TGFβ density using a modified surface ELISA approach17, and 
bioactivity of the surfaces are confirmed by culture with the PE.25 SMAD2 reporter cell line27.  
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When VICs are cultured on tethered TGFβ surfaces, myofibroblast populations are increased in a 
concentration dependent manner, for soft, intermediate, and stiff substrate elasticity hydrogels.  
We further demonstrate the utility of this protein tethering approach by photolithographically 
patterning surface features onto PEG hydrogels, and using these features to investigate modes of 
calcific nodule formation and multicellular responses on stiff substrates.  This platform provides 
a powerful tool to study, in-vitro, effects of the cellular microenvironment on VIC activation. 
 
6.3 Materials and Methods. 
Materials 
All chemicals were purchased from Sigma-Aldrich unless otherwise noted. 
 
Monomer synthesis 
 4-arm PEG-OH (Mn=10,000) was purchased from JenKem USA and functionalized with 
terminal norbornene groups as previously described28.  Briefly, 5-norbornene 2-carboxylic acid 
(5 equivalents: hydroxyls) was dissolved in dichloromethane, to which was added 5x 
dicyclohexylcarbodiimide.  The solution was mixed at room temp for not less than ten minutes.  
4-arm PEG-OH was dissolved in DCM with 5x pyridine, 0.5x 4-(dimethylamino)pyridine.  The 
PEG solution was then added to the norbornene/DCC vessel, and the reaction proceeded 
overnight under argon and mixing.  The resulting product was precipitated into ice-cold ethyl 
ether and washed via soxhlet extraction into ether. 
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Thiol-ene PEG hydrogel synthesis 
 Recombinant TGFβ isoform 1 (Peprotech) was used throughout this study.  TGFβ was 
thiolated by reaction with 2-iminothiolane (Pierce) for 1 hour at room temperature, and the 
product was diluted in 2 mg/mL BSA for storage at -20° C.  4-arm PEG norbornene (PEG-4-NB) 
was crosslinked with PEG di(thiol), Mn=2,000 at 10-wt% PEG-4-NB, and all gels were 
formulated with 1 mM of the CRGDS adhesion peptide.  The photopolymerization was initiated 
with lithium acylphosphinate (LAP)29, present at a concentration of 1 mM, at an intensity of Io= 
10 mW/cm2 (λ=365 nm).  Hydrogels were formed of varying elasticity by changing the ratio of 
(thiol: norbornene) in the initial monomer formulation. 
 PEG hydrogels were functionalized with tethered TGFβ through a secondary thiol-ene 
photocoupling.  All hydrogels were formed with excess norbornene functional group 
concentration.  Prior to tethering, hydrogels were swollen in a solution of 0.05% Irgacure-2959 
for not less than 15 minutes.  Thiolated TGFβ (0, 5, or 50 nM) was added to the gel surface, and 
the gel was photopolymerized (Io=3.5 mW/cm2, λ=365 nm) for approximately 30 seconds.  
Relative surface density of TGFβ was analyzed via a modified surface ELISA, as reported 
elsewhere17.  Bioactivity of the TGFβ functionalized hydrogels was confirmed with the PE.25 
cell line27.  PE.25 cells were seeded onto tethered TGFβ hydrogels in a 24-well plate (100,000 
cells/well) and incubated overnight in serum-free Dulbecco’s modified Eagle medium.  Cells 
were incubated for 10 minutes in Glo-lysis buffer (Promega), frozen for not less than 2 hours at -
70°C, and incubated with luciferase substrate (Promega).  Lysate luciferase activity was 
measured using a Biotek H1 spectrophotometer. 
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Valvular interstitial cell isolation 
Primary VICs were isolated from aortic leaflets, which were excised from freshly 
slaughtered porcine hearts (Hormel) within 24 hours. The leaflets were subjected to a sequential 
collagenase digestion as previously described by Filip et al.30, aliquoted and stored in liquid 
nitrogen.  Briefly, the leaflets were incubated in Earle’s balanced salt solution containing 250 
U/mL collagenase for 30 minute to remove the endothelial cells, followed by a 60-minute 
incubation in fresh collagenase solution and vortexing to remove the VICs. The VIC suspension 
was filtered using a 100µm strainer to remove the degraded leaflets and centrifuged at 1000rpm 
for 10 minutes. The VIC pellet was resuspended in Media 199 (Gibco) supplemented with 15 
v/v% fetal bovine serum (FBS), 0.4 v/v% amphotecerin, and 2 v/v% penicillin/streptomyocin 
(i.e., growth media), plated on TCPS dishes, and cultured to 70% confluency at 37 °C and 5 % 
CO2. The isolated VICs were then trypsinized, pelleted, and resuspended in 50 v/v% FBS, 45 
v/v% M199 media, and 5 v/v% dimethyl-sulfoxide (DMSO) to 1,000,000 cells/mL. This VIC 
suspension was transferred to cryovials in 1 mL fractions, which were then placed in a slow 
temperature gradient freezing box at -70°C overnight, then stored in liquid nitrogen until needed 
for culture.   
 
Valvular interstitial cell culture 
PEG hydrogels were prepared as described above, and then sterilized by incubating with 
70% ethanol for ten minutes, followed by incubation overnight in sterile PBS augmented with 2 
v/v% penicillin/streptomyocin, 0.4 v/v% amphotecerin, and 0.4 v/v% gentamicin.  VICs were 
seeded onto PEG hydrogels at 10,000 cells/cm2 or 20,000 cells/cm2 for activation or nodule 
formation studies, respectively. The VICs were cultured in 1 v/v% FBS M199 media to prevent 
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proliferation during the experiment and cultured for 3 or 5 days for activation or nodule studies, 
respectively. Media was changed every 3 days.  
 
Analysis of VIC activation 
 After 72 hours culture on PEG hydrogels, cell/hydrogel constructs were fixed in 10 % 
formalin overnight at 4°C.  Samples were washed with 0.05 wt% Tween-20 PBS (PBST) 3 times 
for 5 minutes each, blocked in 1 % BSA for 1 hour, and then incubated for 1 hour in mouse anti 
α-smooth muscle actin (αSMA) (abcam) diluted 1:200 in 1 % BSA, both at room temperature.  
Following washing, samples were incubated in goat anti-mouse Alexa488 (invitrogen) diluted 
1:300 in 1% BSA for 1 hour at room temperature.  Samples were then incubated for 5 minutes at 
room temperature with DAPI (invitrogen) diluted 1:1000 in diH2O and washed prior to imaging.  
Images were collected using a Zeiss LSM model 710 confocal microscope.  The percentage of 
activated VICs was determined by manually counting VICs with fibrous αSMA and normalizing 
to the number of cell nuclei, using ImageJ software.   
 
Analysis of calcific nodule formation 
Calcific nodules were stained by fixing samples in 10% formalin solution overnight at 
4°C and incubated in 1% alizarin red S for 2-4 minutes at room temperature. Brightfield images 
were collected on a Nikon inverted microscope and analyzed using ImageJ software for the 
number of nodules present. 
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6.4 Results.  
PEG hydrogel elasticity regulates VIC activation 
 Thiol-ene hydrogels were formed with tunable substrate elasticity as seen in Figure 6.1. 
The four-arm PEG norbornene (PEG-4-NB) was held at a constant concentration (40 mM 
norbornene) in the initial monomer solutions, while the relative ratio of thiol:ene was varied 
from 0.5 to 1.0.  The lowest thiol:ene ratio of 0.5 formed gels with an equilibrium modulus of 0.4 
± 0.1 kPa (E), while increasing the ratio to 0.67 resulted in a gel of 3.4 ± 0.1 kPa.   Increasing the 
ratio of thiol to ene increased the gel elasticity; at a thiol:ene ratio of 0.75, gels had a 
compressive modulus of 11.6 ± 0.9 kPa kPa, and the highest ratio (0.90) formed gels with a 
modulus of 23.1 ± 0.6 kPa.  Collectively, these formulations spanned a range of elasticities of 
interest for VIC cultures1, 13, 26. 
 
Figure 6.1 PEG hydrogel elasticity was tuned by varying the ratio of thiol to ene functional 
groups in the initial monomer solution.  Specifically, PEG-4-NB (Mn=10,000) was crosslinked 
with varying concentrations of PEG bis(thiol) (Mn=2,000), allowed to equilibrate, and 
characterized using rheometrical analysis.  Results are presented as the monomer functional 
group ratio, and the dashed line demarks the 15 kPa threshold for VIC activation. 
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 VICs were seeded onto thiol-ene hydrogels formed at three thiol:ene ratios: soft (0.67), 
intermediate (0.75), and stiff (0.90), and cultured for three days in 1% FBS media to minimize 
proliferation.  At day three, cells were fixed and stained for αSMA production, as seen in Figure 
6.2.  While VICs cultured on soft PEG hydrogels exhibited little αSMA expression (Figure 
6.2A), production was increased on intermediate and stiff substrates (Figure 6.2B, C).  
Quantification of activation level on each substrate was calculated as the number of αSMA 
positive cells divided by the number of nuclei; results are presented in Figure 6.3.  These 
findings agree with previously published work showing a 15 kPa VIC activation threshold, 
defined as greater than 50% of cells positive for αSMA26.   
 
Figure 6.2 VIC activation on PEG hydrogels of varying elasticities.  αSMA is stained green, 
while nuclei are blue.  A) VICs on soft PEG gels had minimal levels of αSMA fibers, but cells 
seeded on B) intermediate or C) stiff gels had higher levels of organized αSMA fibers.  Scale bar 
is 100 µm.   
100 nM
!" #
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Figure 6.3 VIC activation as a function of thiol:ene ratio.  VICs were seeded on thiol:ene 
hydrogels formed at 0.67, 0.75, or 0.90 thiol:ene ratio.  At the lowest elasticity (0.67 thiol:ene), 
36% of the cells were positive for αSMA fibers, an indicator of activation, while on intermediate 
substrates (0.75), 50% of the VICs were activated.  At the stiffest composition of 0.90 thiol:ene 
ratio, 56% of the cells were positive for αSMA fibers. 
 
Characterization of bioactive tethered TGFβ hydrogels 
 Next, thiol-ene PEG hydrogels were formed with surface-tethered TGFβ by using a 
secondary thiol-ene photocoupling reaction.  Preformed thiol-ene gels were incubated with 
thiolated TGFβ (0, 12.5, 25, 50, or 100 nM) and exposed to light (Io=3.5 mW/cm2, λ = 365 nm) 
for 30 seconds, then swollen to remove unconjugated growth factor.  TGFβ surface density was 
then characterized using a surface ELISA (Figure 6.4A), as well as by seeding gels with the 
PE.25 TGFβ reporter cell line (Figure 6.4B). 
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Figure 6.4 PEG hydrogels formed with tunable concentrations of bioactive tethered TGFβ.  
Thiolated TGFβ was tethered to PEG hydrogels formed with excess norbornene concentration 
using a photoinitiated thiol-ene reaction.  TGFβ surface density was tuned by changing the 
concentration of thiolated TGFβ in the patterning solution.  A) Surface ELISA results confirm a 
tunable detectable TGFβ surface, while B) bioactivity was confirmed by seeding the gels with 
the PE.25 reporter cell line.  In each plot, error bars represent s.e.m. (n=4).  Gels were formed at 
0.9 thiol:ene ratio and equilibrated in 0.05 wt% I-2959 initiator prior to photocoupling thiolated 
TGFβ (Io = 3.5 mW/cm2, λ=365 nm, t = 15 sec). 
 
 Results demonstrate that the photocoupling approach is viable for forming gel surfaces 
with tunable concentrations of TGFβ, as characterized via antibody detection and that these gel 
surfaces present a bioactive signal to cells.    
 
VIC activation on tethered TGFβ surfaces 
 Thiol-ene PEG hydrogels were formed using the 0.67, 0.75, or 0.9 thiol:ene ratios as 
previously characterized with respect to levels of VIC activation, and then photopatterned with 
either 5 or 50 nM thiolated TGFβ.  The gels were swollen to remove any non-coupled growth 
factor, then seeded with VICs and cultured for 3 days.  Following culture, cells were fixed and 
stained for αSMA production.  Results are included in Figure 6.5.  The softest gels (lowest 
elasticity) had few cells that were positive for αSMA fibers, regardless of the TGFβ 
concentration (Figure 6.5 A, D).  In contrast, higher stiffness substrates exhibited high levels of 
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activated cells, and this trend was only increased in the presence of the TGFβ signal (B, C, E, 
and F in Figure 6.5).  In addition, at both 5 and 50 nM tethered TGFβ, multicellular nodule-like 
formations were also observed, as represented in Figure 6.5.  Previous studies have shown the 
importance of persistent αSMA expression as a precursor to the nucleation of nodules1, 31. 
 
Figure 6.5. VIC activation on tethered-TGFβ hydrogel surfaces.  Thiol-ene hydrogels of varying 
elasticity were photopatterned with thiolated TGFβ, at either 5 nM (A, B, and C) or 50 nM (D, E, 
and F), then seeded with VICs and cultured for three days. Gels were formed at soft (A,D), 
intermediate (B, E), or stiff (C, F) elasticity.  Soft gels had the least level of organized αSMA 
staining, regardless of TGFβ surface density.  Intermediate and stiff gels exhibited much higher 
levels of αSMA, relative to hydrogels with no surface conjugated TGFβ (Figure 6.2). Tethered 
TGFβ gels at intermediate and stiff elasticity also exhibited multi-cellular nodules, as seen in 
panels B, C, E, and F.  Scale bar is 100 µm. 
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6.5 Discussion. 
VIC activation on PEG hydrogels 
 As substrate elasticity is one factor that contributes to the activation of VICs, it was 
important to characterize the role of monomer choice and functionality on equilibrium modulus 
for these photopolymerized thiol-ene PEG hydrogels.  Varying the ratio of functional groups 
from 0.5 to 0.9 (thiol:ene) resulted in hydrogels with elasticity ranging from ~0.5 to 23 kPa (E).  
Since previous studies have reported a threshold modulus of 15 kPa for VIC activation26, this 
approach confirmed that such a thiol-ene hydrogel platform could be used to synthesize materials 
with a range of elasticities of interest for VIC activation.  In addition, each gel formed contained 
an excess ene concentration, providing a reactive handle for subsequent patterning of thiol-
containing moieties, and particularly thiolated proteins, of interest.   
 When VICs were seeded on soft gels (0.67 thiol:ene, E = 3.4 kPa), the cells expressed 
low levels of organized αSMA, indicating minimal activation levels as expected for this soft 
substrate.  Increasing the ratio of thiol:ene to 0.75 produced an intermediate stiffness material 
(E=11.6 kPa), and VICs cultured on intermediate gels exhibited a higher level of fibrous αSMA.  
The stiffest hydrogel substrate was formed at a 0.9 thiol:ene ratio (E = 23 kPa), and VICs on this 
surface expressed the highest levels of αSMA fibers, as seen in Figure 6.2.  VIC activation was 
quantified by counting the number of cells that were positive for αSMA fibers, and normalizing 
to the number of DAPI-stained nuclei.  Results (Figure 3) confirm the trend of increasing VIC 
activation as a function of increased hydrogel elasticity and support previously published work 
with other gel systems1, 26. 
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TGFβ-modified hydrogel surfaces 
 Hydrogels were formed with an excess concentration of ene relative to the total thiol 
concentration, in order to form hydrogels with pendant norbornene functional groups.  This 
approach provided a simple method to subsequently modify the PEG gel chemistry using the 
photoinitiated thiol-ene reaction to conjugate thiolated biological signals.  Here, TGFβ was 
thiolated via reaction with 2-iminothiolane, and this thiolated TGFβ was subsequently 
photoconjugated onto PEG hydrogel surfaces using this approach.  Because the reaction is 
photochemically controlled, the reaction rate can be controlled by the light dose, and the reaction 
can be confined to specific spatial regions, allowing photopatterning.  In this contribution, TGFβ 
surface density on the gels was tuned by changing the concentration of thiolated TGFβ in the 
patterning solution, as characterized by a surface ELISA (Figure 6.4A).  In order to more fully 
characterize the activity of the tethered TGFβ surfaces, gels were seeded with PE.25 cells, an 
epithelial line permanently transfected with a luciferase reporter gene for SMAD2 activity27, 32.  
PE.25 cell culture confirmed the bioavailability of TGFβ tethered onto thiol-ene hydrogel 
surfaces, with a similar dose response to that observed via our surface ELISA. 
 
VIC activation on photopatterned TGFβ hydrogels 
 VICs were seeded on thiol-ene hydrogels formed with 0.67, 0.75, or 0.90 monomer thiol-
ene ratio, as described previously.  Following gelation, the hydrogels were surface modified with 
thiolated TGFβ (5 or 50 nM) using a secondary thiol-ene reaction to create surfaces with varying 
densities of this cytokine.  VICs were seeded onto the tethered TGFβ hydrogels and cultured for 
three days, and then fixed and stained for αSMA.  Cells on the lowest elasticity (E ~ 3.5 kPa) 
had low levels of αSMA-positive cells, similar to that on soft gels with no tethered TGFβ.  This 
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result was quite interesting as TGFβ is a potent activator of myofibroblasts, including VICs18, 20, 
33, and thus, alludes to the influence of the context of the microenvironment in determining the 
response of VICs to TGFβ.  Interestingly, TGFβ tethered to intermediate (~12 kPa) or stiff (~23 
kPa) hydrogels promoted VIC activation at levels higher than that of non-patterned substrates.  
Additionally, for both tethered TGFβ concentrations tested, VICs seeded on intermediate and 
stiff surfaces also formed multicellular nodules, another indicator of a myofibroblast-like 
phenotype.  Benton et al. showed that αSMA production is necessary for VICs to form calcific 
nodules34, and that TGFβ treatment promoted nodule formation on TCPS surfaces with very high 
(on the order of gPa) elasticity.   
 Our observation of nodule formation on softer substrates suggests the importance of the 
context of TGFβ dosing, and we plan to expand the current body of work by utilizing a spatial 
patterning approach for tethering TGFβ.  We have synthesized a thiolated-fluorophor tracer 
molecule that can be mixed with thiolated TGFβ solutions prior to photocoupling, in order to 
visualize areas of a gel surface that have been exposed to a photopolymerization.  We plan to use 
a photolithographic approach to pattern circular “islands” of tethered TGFβ with various 
diameters ranging from 50 to 500 µm.  VICs will be seeded onto these spatially patterned gel 
surfaces, and cultured for 4 days in order to allow nodule formation, following the protocol of 
Benton et al.  This approach should provide insight into the role of exogenous TGFβ delivery 
(i.e. surface tethered) versus paracrine signaling that may occur as cells on the tethered TGFβ 
islands in turn upregulate TGFβ secretion after activation.   
 Alternatively, this spatial patterning technique may also be used to investigate competing 
protein signals.  Cushing et al31. detailed the role that basic fibroblast growth factor (bFGF) 
could play in downregulating VIC activation.  Using thiolated bFGF in conjunction with tethered 
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TGFβ would provide more insight into the competing roles of these two growth factors, and how 
interplay between the two, both of which are commonly ECM-bound in heart valves and other 
tissues. 
 
6.6 Conclusions. 
 Thiol-ene hydrogels were formed using 4-armed PEG norbornene crosslinked with PEG 
bis(thiol) while varying the ratio of thiol:ene functional groups to provide facile control of the 
final equilibrium substrate elasticity.  VICs cultured for three days on hydrogels formed at 0.67 
thiol:ene ratio (soft) gels exhibited low activation levels, as characterized by αSMA fiber 
formation, while greater than 50% of cells on gels formed at 0.75 (intermediate) or 0.90 (stiff) 
thiol:ene ratios were activated. TGFβ was thiolated and tethered onto surfaces of thiol:ene 
hydrogels, utilizing a secondary thiol-ene photocoupling reaction to create tunable surface 
densities of bioactive proteins.  When VICs were seeded on gels patterned with 5 or 50 nM 
tethered TGFβ, there was a minimal increase in activation for cells cultured on soft gels.  VICs 
on tethered TGFβ gels formed at intermediate or stiff substrate elasticity, in contrast, had higher 
levels of activated cells and formed multicellular nodules indicative of a population of 
myofibroblast-like cells.  These results suggest that VIC activation depends strongly on 
microenvironmental context and its response to TGFβ signaling depends on the local mechanical 
environment; thus, thiol-ene hydrogels might be used as a robust platform to investigate the 
cross-talk between these two important factors. 
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Chapter 7 
 
Conclusions and Recommendations 
 
 
 The cellular microenvironment plays a crucial role in governing cellular behavior and 
function.  A more complete understanding of this microenvironment is needed in order to design 
tissue-engineered solutions for a host of applications in regenerative medicine.  However, 
decoupling individual contributions of factors like tissue elasticity or soluble protein 
concentration presents a challenge in-vivo, due to the complexity of signals presented to cells in 
the native extracellular matrix.  One powerful method for studying how cells receive cues from 
their microenvironment is through encapsulation in a synthetic matrix that can be tuned to 
incorporate one or more of these biological cues.   
 In chapter 3, methods to photoencapsulate the cytokine transforming growth factor beta 
(TGFβ) in PEG diacrylate hydrogels were developed.  TGFβ was encapsulated in 10-wt% 
PEGDA hydrogels, using various molecular weights of PEG as the crosslinking molecule.  
While each formulation resulted in hydrogels with mesh sizes adequate for diffusion of TGFβ, 
only the highest molecular weight PEG (Mn=10,000) released an appreciable amount of the 
encapsulated protein, suggesting inadvertent protein-polymer conjugation.  As the acrylate 
concentration was different for each hydrogel tested, TGFβ recovery from non-gelling 
photoinitiated monoacrylate reactions was characterized over a wide range of [acrylate].  While 
high monomer PEG-acrylate concentration increased the amount of TGFβ recovered, as detected 
via ELISA, bioactivity was maximized at intermediate PEG-acrylate concentrations.  
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Collectively, these results suggested PEGylation of the protein, thereby influencing its solubility, 
diffusivity, and activity during encapsulation in PEG hydrogels.  To circumvent some of these 
issues, the protective effects of affinity peptides were next investigated.  Affinity peptides 
WSHW and KRIWFIPRSSWY were tested via SPR techniques to confirm binding affinity for 
TGFβ.  When incubated with affinity peptides, no decrease in TGFβ bioavailability was 
detected.  When affinity peptides were included in PEGDA monomer solutions, increased 
amounts of bioactive, TGFβ were detected, via ELISA and cellular bioactivity assays.  Further, 
affinity peptides increased the amount of TGFβ release and recovery in a dose-dependent 
manner.   
 Having identified photopolymerization conditions that allow the release of soluble, 
bioactive TGFβ from PEGDA hydrogels, this platform might be next utilized as a controlled-
release material.  Affinity peptides, synthesized with an appropriate spacer and terminated with 
cysteine residues, could be easily incorporated into PEG hydrogels using a thiol-acrylate 
polymerization.  Additionally, our finding that affinity peptides helped protect TGFβ during 
photopolymerization could be enhanced by further analysis of the mode of protein inactivation.  
Gel electrophoresis or MALDI mass spectrometry might be used to confirm that TGFβ is 
PEGylated during acryl chain-growth reactions, and the inhibition of such PEGylation by affinity 
peptides could then be shown directly.  Further, knowledge of the specific binding site for each 
peptide sequence could be obtained, through an ELISA where the affinity peptides were used for 
sequestration, in place of antibodies.  If each peptide interacts with a unique binding site, synergy 
between the two sequences is expected, and could enhance tunability of protein-peptide 
interactions for controlled release applications. 
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 In Chapter 4, protein inactivation following exposure to photoinitiated step- and chain-
growth reactions was characterized and compared.  In-situ photorheometry was used to quantify 
the light dosages necessary to form hydrogels via acryl chain-growth and thiol-ene step growth 
mechanisms, using the photoinitiator LAP.  When solutions of lysozyme and LAP were exposed 
to similar ranges of light doses, radically mediated loss of protein function was rapid.  Next, 
model systems based on non-gelling monomer systems (PEG monoacrylate and PEG-4-
norbornene/cysteine) were photopolymerized with lysozyme and TGFβ, at light doses required 
to fully form hydrogels.  The acrylate chain-growth polymerization mitigated some measure of 
lysozyme destruction, as 50% of pre-polymerized activity was retained, but TGFβ was 
completely inactivated.  In contrast, 100% bioactivity was maintained following thiol-ene 
polymerization, for both lysozyme and TGFβ.  To more fully understand the thiol-ene protective 
effect, solution polymerizations of that monomer system were performed at multiple light 
intensities and LAP concentrations.  For a constant exposure time, only the highest LAP 
concentration tested (10 mM) exhibited significant loss of lysozyme activity.  Lysozyme 
destruction in the presence of thiol-ene monomer was then tested for two LAP concentrations, 
0.1 and 10 mM, (Io=10 mW/cm2) where exposure time was varied from 5 to 120 seconds.  When 
protein bioactivity was plotted versus total photogenerated radicals, protein activity was 
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maintained up to a much higher radical concentration than in solutions with no monomer present. 
 
Figure 7.1.  Data adapted from chapter 4 showing protein destruction as a function of 
photogenerated radicals, plotted over identical radical concentration ranges. A) lysozyme and 
LAP, and B) lysozyme, LAP, and thiol-ene monomers.   
 
 These results confirmed that the rapid polymerization kinetics of the thiol-ene reaction 
provide a facile method for gel formation with minimal impact on the bioactivity of an 
encapsulated protein payload.  We theorize that this may be due, in part, to the fact that thiol-ene 
reactions are not oxygen inhibited, in contrast to the acrylate chain-growth reaction.  This means 
thiol-ene polymerizations require lower light dosage and total radicals generated for hydrogel 
formation.  Other possibilities for this thiol-ene protection include differences in the radical 
lifetime for the species involved, or the nature of the radical species itself (i.e. a propagating 
acryl radical in chain-growth vs thiyl or norbornene radicals in the step-growth reaction).  
Although we demonstrated protein protection with lysozyme and TGFβ in this thesis, these 
findings would be enhanced by a more precise understanding of the mode of protein radical 
protection, in order to make this knowledge more universally applicable. 
  With knowledge of how to maintain protein bioactivity during in-situ polymerization, via 
both chain- and step-growth mechanisms, we then applied this approach to form hydrogels that 
incorporated covalently tethered bioactive proteins.  Transforming growth factor beta, a cytokine 
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known to induce numerous cellular processes, was thiolated to provide a facile handle for 
incorporation into PEG hydrogels.  By utilizing either thiol-acrylate or thiol-ene reactions, 
thiolated TGFβ was covalently tethered into hydrogels.  As a first demonstration, we selected the 
PEG diacrylate platform as it has been successfully used to promote chondrogenic differentiation 
of human mesenchymal stem cells (hMSCs), a process in which TGFβ plays a role. 
 In Chapter 5, tethered TGFβ was utilized to promote chondrogenic differentiation of 
encapsulated hMSCs.  TGFβ was thiolated with 2-iminothiolane and shown to retain bioactivity, 
as compared to native growth factor.  Further, the [TGFβ] in PEGDA hydrogels was easily tuned 
by varying the monomer concentration of thiolated protein.  When the PE.25 reporter cell line 
was encapsulated in tethered TGFβ hydrogels, bioactivity of the protein and its ability to signal 
encapsulated cells were confirmed in this 3D culture system.  hMSCs were then encapsulated in 
such tethered growth factor hydrogels to characterize the potential of the functionalized material 
to promote chondrogenic differentiation.  Culture in growth media served as a negative control, 
and chondrogenic media augmented with soluble TGFβ was used as a positive control for 
chondrogenesis.  Over a 21-day culture, cells cultured in gels with either 10 or 100 nM tethered 
TGFβ were positive for chondrogenesis markers, including GAG deposition and collagen-II 
secretion.  Cells in gels with 1 nM tethered TGFβ were positive for collagen-II production, but 
produced GAGs at low levels similar to production of the negative control.  Soluble growth 
factor delivery via media exchange is limited in practical application, while this tethered growth 
factor approach offers promise for materials-based hMSC delivery and cartilage regeneration 
therapies. 
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Figure 7.2.  Persistence of TGFβ signaling in 2- and 3D systems.  PE.25 cells were plated (A) or 
encapsulated in PEGDA hydrogels (B) with native and thiolated TGFβ.  Luciferase activity was 
normalized to day 0 signal, and each day was normalized to double-stranded DNA content.  
  
 As proteins are covalently linked into the 3D encapsulating hydrogel in this model, TGFβ 
cannot be endocytosed, as would occur in soluble culture experiments.  Thus, this tethered 
protein platform might be used as a tool to study persistent growth factor presentation and 
protein signaling dynamics in a novel 3D presentation.  This work could also be complemented 
by characterization of the persistence of a tethered protein on cell signaling, both in-vitro and in-
vivo.  If the thioesther bond that links thiolated proteins to the acryl-PEG hydrogel was suitably 
stable, i.e. for a time period of weeks or months, this approach could have application as a 
method for cell recruitment and differentiation.  For instance, if a cell-invasive tethered TGFβ	  
hydrogel could be implanted into a cartilage defect, the stem cells released by microfracture 
surgery might be retained and differentiated in the area of need, improving patient outcome.  
 TGFβ also plays a role in numerous other cellular functions, including chemotaxis, 
apoptosis, and immunological responses including fibrosis and dendritic cell activation.  TGFβ 
can also induce the activation of valvular interstitial cells, promoting a fibroblast to 
myofibroblast transition.  This myofibroblast phenotype is indicative of a diseased state, with 
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increased production of α-smooth muscle actin fibrils and calcific nodule formation in-vivo.  
These activated VICs then play a role in upregulation of ECM implicated in causing valve 
stiffening, ultimately leading to loss of function.  
 In Chapter 6, thiol-ene hydrogels were used to probe the role that cellular 
microenvironmental factors play in promoting the fibroblast to myofibroblast transition.  A 
hydrogel platform with 1) tunable mechanical stiffness and 2) unreacted norbornene 
functionality were synthesized and characterized.  By controlling the relative ratio of 
norbornene: thiol (ene:thiol) in the initial monomer formulation, the resulting hydrogel elasticity 
was tuned.  Previous work from our group has shown that VICs cultured on hydrogels with 
elasticity below a 15 kPa (E) threshold maintain a quiescent phenotype, but are activated upon 
cultured on gels with stiffnesses above this threshold.  Using an ene:thiol ratio of 0.67 provided a 
culture substrate of ~3.5 kPa (E), while a stiffer hydrogel was formed using a ratio of 0.9, for a 
swollen modulus of ~23 kPa (E).  To further characterize this system, an intermediate substrate 
elasticity of ~12 kPa (E) was obtained using an ene:thiol ratio of 0.75.  To confirm these ranges 
for activation of VICs, cells were cultured on the low, intermediate, and stiff modulus gels and 
stained for αSMA fiber formation.   
 This thiol-ene protein patterning approach has exciting utility for studying complex cell-
protein interactions.  For the VICs-TGFβ system, we are currently conducting studies whereby 
photolithographic techniques are used to pattern various “islands” of TGFβ on an otherwise inert 
surface.  This approach for spatial TGFβ patterning will allow us to answer questions about the 
myofibroblast activation cascade, and whether small regions of initial TGFβ activation can 
influence disease progression across larger cell numbers.  Alternatively, the growth factor basic 
fibroblast growth factor (bFGF) can prevent TGFβ-induced activation of VICs.  Patterning 
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surfaces with thiolated bFGF could provide a negative control for activation via TGFβ delivered 
solubly, or the two factors could be patterned concurrently to investigate the dynamic interaction 
between the two signals and implications of each on valve tissue homeostasis. 
 This excess-[ene] hydrogel platform has application for other cell-protein systems, 
especially for cell functions like migration and others where protein gradients are important.  As 
an example, TGFβ is implicated in metastasis of melanoma cells, an event that results in greatly 
increased mortality.  Culturing melanoma cells in or on tethered TGFβ hydrogel may provide 
insight into physiologically relevant TGFβ concentrations required to cause metastasis.  Further, 
using the “moving platform” approach for the photopatterning thiol-ene reaction, as others have 
demonstrated to create 3D gradients of thiolated peptides, would allow patterning of complex 
spatial gradients in TGFβ or other proteins.  Beyond melanoma metastasis, such a platform 
would also have utility for the development of materials that guide axonal outgrowth using 
tethered glial derived neurotrophic factor (GDNF), promote ingrowth of hMSCs via tethered 
stromal differentiation factor 1 (SDF-1), and even Noggin or sonic hedgehog (ShH) for control 
of embryonic stem cell differentiation. 
 In summary, this thesis presents a framework for maximizing the stability of proteins 
present during photoinitiated radical polymerizations, and makes use of that framework in order 
to develop biomaterial platforms capable of presenting bioactive protein cues to surrounding 
cells.  These methods provide for facile incorporation of bioactive proteins into synthetic 
hydrogel materials, with tunable spatially controlled concentrations.  Such 3D cell scaffolds can 
be used to study and control complex interactions between cells, signaling proteins, and culture 
substrates in a physiologically meaningful context.   	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